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(57) ABSTRACT 
The present disclosure relates to the synthesis of non-natural 
analogs of S-adenosyl-L-methionine (SAM) and/or of Se­
adenosyl-L-methionine (SeAM) by reacting a methionine 
analog and adenosine triphosphate (ATP) in the presence of 
at least one methionine adenosyltransferase (MAT), and to 
use thereof with downstream SAM and/or SeAM utilizing 
enzymes. The non-natural analogs of SAM and/or SeAM 
have the general formula: 
where X is S or Se, and R1 is an alkyl group. 
13 Claims, 13 Drawing Sheets 
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1 
SYNTHESIS OF NON-NATURAL COFACTOR 
ANALOGS OF 
S-ADENOSYL-L-METHIONINE USING
METHIONINE ADENOSYLTRANSFERASE 
2 
summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea­
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
RELATED APPLICATION 
5 feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this summary or not. To avoid 
excessive repetition, this summary does not list or suggest 
all possible combinations of features. This application claims priority from U.S. Provisional 
Patent Application No. 61/832,038, filed Jun. 6, 2013, the 
entire disclosure of which is incorporated herein by this 10 
reference. 
TECHNICAL FIELD 
The presently-disclosed subject matter generally relates to 15 
the synthesis of non-natural cofactor analogs of S-adenosyl­
L-methionine (SAM) and/or of Se-adenosyl-L-methionine 
(SeAM) and to the various use(s) thereof. 
INTRODUC TION 20 
Methionine adenosyltransferase (MAT) is a family of 
enzymes that utilizes adenosine triphosphate (ATP) and 
methionine as substrates to produce S-adenosyl-L-methio­
nine (SAM or AdoMet), a methyl donor in the biological 25 
methylation of biomolecules and bioactive natural products. 
(FIG. 1) [42]. The reaction occurs in an unusual two-step 
mechanism in which the adenosyl group is transferred from 
ATP to the sulfur atom of methionine, cleaving the triphos­
phate, and the triphosphate is subsequently hydrolyzed to 30 
PPi and Pi [45]. 
MAT is present in all living organisms, from bacteria to 
mammals. To date, MAT structures from E. coli [40], 
Thermococcus kodakarensis [ 48], Burkholderia pseudomal-
lei (PDB code 3IML), Entamoeba histolytica (PDB code 35 
3S04), Mycobacterium marinum (PDB code 3RV2), Myco­
bacterium avium (PDB code 3S82), Mycobacterium tuber­
culosis (PDB code 3TDE), Rattus norvegicus f36] and 
Homo sapiens [50] have been solved. They are more than 
50% identical to one other and share several common 40 
features: (i) they usually appear as oligomeric proteins with 
a highly conserved three-domain fold [43]; (ii) divalent 
cations such as Mg2+ are required for activity and monova­
lent cations such as K+ is able to enhance the reaction rate
[ 44]; (iii) a flexible loop suspended above the active site, 45 
serves as a "gate" and is involved in the catalytic activity of 
the enzyme [34]. 
Moreover, some specific analogs of SAM bearing alter­
native alkyl substitution for the native methyl group have 
been successfully used in vitro for the methyltransferase- 50 
catalyzed alkylation of natural products [57], DNA [58], and 
proteins [59]. While these recent studies suggest M Tases 
tolerate alternative SAM alkyl donors, the methods pro­
posed in such studies remain impractical due to a number of 
key factors. For example, previously known synthetic routes 55 
to SAM analogs are multistep strategies that suffer from 
poor overall yields and difficult purification protocols. In 
addition, the corresponding SAM analogs are often highly 
labile and are unable to pass through the cell membranes. 
Accordingly, there is a need in the art for a simple method 60 
of providing improved non-natural SAM analogs. 
BRIEF SUMMARY 
This summary describes several embodiments of the 65 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
In some embodiments, the present disclosure is directed 
to the synthesis of non-natural L-methionine and/or L-sele­
nomethionine analogs and to uses thereof. Accordingly, in 
certain embodiments, the present disclosure provides com-
pounds of the Formula II: 
(II) 
wherein R1 is any alkyl group. In certain embodiments, R1 
comprises a propyl group, an ally! group, an aryl group 
and/or a propargyl group. Further, in some embodiments, R1 
is selected from the group consisting of 
US 9,879,043 Bl 
3 4 
Likewise, the present disclosure provides, in some 
embodiments, methods of producing an indolocarbazole 
analog. Such methods comprise the step of reacting a first 
substrate with a second substrate in the presence of a 
5 methionine adenosyltransferase (MAT). 
In some embodiments of the methods provided herein, the 
first substrate comprises a compound according to Formula 
II, the second substrate comprises adenosine triphosphate 
(ATP) and/or the MAT comprises at least one of human 
10 MAT II catalytic alpha and regulatory beta subunit 
(hMAT2), human MAT II catalytic alpha subunit alone 
(hMAT2A), human MAT I catalytic subunit alpha 
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol­
fataricus MAT (sMAT), and Methanocaldococcus janna-
15 schii MAT (mMAT). Additionally, the present disclosure 
provides that any of the methods described herein may be 
conducted in one pot, i.e., in a single vessel. 
And in some embodiments, X is selected from the group 
consisting of S and Se. In still further embodiments, R 1 is 20 
selected from the group consisting of 
The present disclosure further presents a method for 
production of a chemical library, the method comprising at 
least the step of reacting a plurality of compounds according 
to Formula II with ATP in the presence of at least one MAT 
to obtain at least one non-natural compound. In some 
embodiments, the at least one non-natural compound is a 
lx�s'v/',("°" 
NH2 
NH2 
/X�S�COOH, and 
/X� S �COOH 
NH2 
and X may be S. 
In some embodiments, the present disclosure is directed 
to the synthesis of non-natural cofactor analogs of S-adeno­
syl-L-methionine (SAM) and/or Se-adenosyl-L-methionine 
(SeAM) using methionine adenosyltransferase and to uses of 
the non-natural SAM and/or SeAM analogs. Accordingly, in 
some embodiments, the present disclosure provides a SAM 
analog and/or a SeAM analog of the Formula I: 
(I) 
wherein R is a compound according to Formula II and 
wherein R is attached through an S or Se atom and/or 
through the X atom. In certain embodiments, R comprises 
methionine-tetrazole. 
Further, the present disclosure also provides, in certain 
embodiments, methods of producing an S-adenosyl-L-me­
thionine analog and/or a Se-adenosyl-L-methionine (SeAM) 
analog, comprising at least the step of reacting a first 
substrate with a second substrate in the presence of a 
methionine adenosyltransferase (MAT). 
25 
SAM analog and/or a SeAM analog. 
Furthermore, the present disclosure also provides, in 
certain embodiments, a method of producing a SAM analog 
by reacting a first substrate comprising methionine-tetrazole 
with a second substrate in the presence of at least one 
methionine adenosyltransferase (MAT). Moreover, in some 
30 embodiments, the second substrate comprises ATP. And in 
some embodiments, the MAT comprises at least one of 
human MAT II catalytic alpha and regulatory beta subunit 
(hMAT2), human MAT II catalytic alpha subunit alone 
(hMAT2A), human MAT I catalytic subunit alpha 
35 (hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol­
fataricus MAT (sMAT), and Methanocaldococcus janna­
schii MAT (mMAT). 
In some embodiments, the present disclosure provides a 
method for producing a natural product analog, comprising: 
40 (i) reacting a methionine analog and at least one methionine 
adenosyltransferase to produce an S-adenosyl-L-methionine 
analog in a vessel; (ii) providing at least one methyl trans­
ferase and at least one natural product in the vessel; and (iii) 
alkylating the natural product in the presence of the methyl 
45 transferase and the S-adenosyl-L-methionine analog to pro­
duce a natural product analog in the vessel. In some embodi­
ments, the methionine analog is a compound according to 
Formula II, as described herein. And in certain embodi­
ments, S-adenosyl-L-homocysteine hydrolase is also pro-
50 vided in the vessel. 
55 
DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates a reaction catalyzed by MAT. 
FIG. 2 shows representative methylated natural products 
where methyl groups deriving from SAM via MT-catalyzed 
methylation are highlighted as spheres. AT3 (AT2433); CLC 
(colchicine); ESP (esperamicin); EVM (evemimicin); GLM 
(geldamycin); MGM (megalomicin); and NGM (nogalamy-
60 cin) are presented. 
FIG. 3 provides a methionine adenosyltransferase (MAT)­
catalyzed reaction, where L-Met (R=CH3, X=S) is the 
native substrate leading to native product S-adenosylmethio­
nine (R=CH3, X=S). The variability of both R and X is 
65 described within the present disclosure. 
FIG. 4 presents the general methodology for the synthesis 
of S- and Se-L-Met analogs (X=S and Se, respectively) (i) 
US 9,879,043 Bl 
5 
Na, NH3, -78
° C. with 1 or 1-Se; (ii) K2C03, acetone with
1-Hcy; (iii) NaBH4/NaOH, H20, THF, 5 h with 1-Se; (iv)
HCl, Reflux with 2-Se (see Table 1).
FIG. 5 illustrates the turnover of S/Se-Met analogs to the 
corresponding S(Se )AM analogs catalyzed by selected 5 
MATs based upon reverse phase high performance liquid 
chromatography (RP-HPLC) (average percent errors5%). 
Notably, no product formation was observed in the absence 
of MAT, S/Se-Met analogs or ATP. 
FIG. 6 provides the structures of the S/Se-Met analogs 10 
listed in FIG. 5 (X=S, Se). 
FIG. 7 presents mapping of residue positions that differ 
among eMAT (Protein Data Bank (PDB) ID:1RG9), 
hMAT2A (PDB ID:2P02) and hMATlA (PDB ID:20BV) 
on the hMAT2A homodimeric structure. Conserved residues 15 
among all three MATs are indicated by grey ribbons; resi­
dues that differ among all three MATs are highlighted as ball 
and stick models; and conserved residues among 'stringent' 
MATs (hMATlA and eMAT) which differ from the more 
permissive hMAT2A are highlighted by lighter-colored ball 20 
and stick models. 
FIG. 8 provides the products of hMAT2A-RebM coupled 
reaction in the presence of 3/3-Se, 7 /7-Se, 4/4-Se, and 6/6-Se 
(see FIG. 5, FIG. 6). The percent product formation is noted 
in parentheses based upon the S/Se-Met analogs utilized 25 
( average percent errors5% ). 
FIG. 9 shows the synthesis of S/Se-alkylated L-methio­
nine analogs, when "a" is NaN3, nBu4NHS04, NaHC03 
(sat)/CH2Cl2; 
FIG. 10 shows the synthesis of S/Se-alkylated L-methio- 30 
nine analogs, when "b" is Na, NH3, -78
° C.
FIG. 11 shows the synthesis of S/Se-alkylated L-methio­
nine analogs, when "c" is K2C03, acetone. 
6 
Light-colored bars (referring to branched L-alkyl-substi­
tuted analogs) denote analogs for which only trace turnover 
was observed with MATs studied to date. As controls, no 
product formation was observed in the absence of sMAT, 
S/Se-Met analogs or ATP. 
FIG. 17 provides HPLC traces for representative sMAT 
reactions illustrating the production of SAM analogs and/or 
5'-methyl-thio(seleno )-5'-deoxyadenosine (MTA) in the 
presence of a select set of L-Met analogs. Starting material 
(ATP) is designated by a dot. 
FIG. 18 shows an example of a synthesis of (seleno) 
methionine analogs, high-throughput MAT assay, and prod­
uct verification via LC/MS. 
FIG. 19 illustrates a reaction catalyzed by MAT. 
FIG. 20 presents the synthesis of methionine tetrazole 
(T-met), where: (a) is (Boc)20, pyridine, NH4HC03, rt, 5 h, 
70-8-%; (b) is (TFA)20: pyridine (1:1), THF, 0
° C., 3 h,
85-95%; (c) is NaN3, ZnBr2, H20/2-propanol (2:1), 80
° C.,
16 h, 80-90%; and (d) is Et2NH, CH2Cl2, 0.5 h, 80-94%.
FIG. 21 provides data illustrating the stability of SAM-T 
relative to native SAM. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMEN TS 
The details of one or more embodiments of the presently­
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem­
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be FIG. 12 shows the synthesis of S/Se-alkylated L-methio­
nine analogs, when "b" is Na, NH3, -78
° C.
FIG. 13 shows the synthesis of S/Se-alkylated L-methio­
nine analogs, when "d" is NaBHiNaOH, H20, THF, rt 
(room temperature), 5 h. 
35 understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
Each example is provided by way of explanation of the 
present disclosure and is not a limitation thereon. In fact, it 
will be apparent to those skilled in the art that various FIG. 14 shows the synthesis of S/Se-alkylated L-methio­
nine analogs, when "e" is HCl, reflux. 
FIG. 15 provides high performance liquid chromatogra­
phy (HPLC) traces for representative reactions. The first 
column (left/bottom) provides representative reactions 
(Method D) catalyzed by hMAT2 illustrating the production 
40 modifications and variations can be made to the teachings of 
the present disclosure without departing from the scope of 
the disclosure. For instance, features illustrated or described 
as part of one embodiment can be used with another embodi-
of Se-SAM analogs ( denoted by a black dot) in the presence 45 
of a select set of L-SeMet analogs. Starting material (ATP) 
is designated by a star. The second column (middle) pro­
vides representative reactions (Method D) catalyzed by 
hMAT2 illustrating the production of SAM analogs ( denoted 
by a black dot) and/or 5'-methyl-thio-5'-deoxyadenosine 50 
(MTA, designated by a 'X') in the presence of a select set 
ofL-Met analogs. Starting material (ATP) is designated by a 
star and the SAM degradation product, adenine, is labeled 
with an 'A'. The third column (right/top) provides represen­
tative hMAT /RebM coupled reactions (Method E) where the 55 
peaks corresponding to differentially alkylated products are 
highlighted by the black dot and peaks at 'S' and 'M' 
correspond to the remaining substrate and methylated prod­
ucts, respectively. A small amount of methylated product is 
formed in the control lacking L-MetlL-Met analog (bottom 60 
panel), suggesting purified hMAT2 and/or RebM retains a 
small amount of residual L-Met and/or SAM. For all chro­
matograms illustrated, numbers within each correspond to 
the Se-Met or S-Met analogs utilized. 
ment to yield a still further embodiment. 
All references to singular characteristics or limitations of 
the present disclosure shall include the corresponding plural 
characteristic(s) or limitation(s) and vice versa, unless oth­
erwise specified or clearly implied to the contrary by the 
context in which the reference is made. 
The methods and compositions of the present disclosure, 
including components thereof, can comprise, consist of, or 
consist essentially of the essential elements and limitations 
of the embodiments described herein, as well as any addi­
tional or optional components or limitations described 
herein or otherwise useful. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, some defini­
tions are set forth to facilitate explanation of the presently­
disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
FIG.16 illustrates the turnover of S/Se-Met analogs to the 
corresponding S(Se )AM analogs catalyzed by sMAT based 
upon RP-HPLC (average percent errors5%, see Table 4). 
65 those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
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Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer­
ence to "a fluorophore" includes a plurality of such images, 
and so forth. 
8 
The term "substrate" means a substance that is acted upon 
by an enzyme in a chemical reaction. 
As used herein, the term "substituted" is contemplated to 
include all permissible substituents of organic compounds. 
In a broad aspect, the permissible substituents include acy­
clic and cyclic, branched and unbranched, carbocyclic and 
heterocyclic, and aromatic and nonaromatic substituents of 
organic compounds, peptides, lipids, oligonucleotides, and 
oligosaccharides. Illustrative substituents include, for 
Unless otherwise indicated, all numbers expressing quan­
tities, properties, and so forth used in the specification and 
claims are to be understood as being modified in all 
instances by the term "about". Accordingly, unless indicated 
to the contrary, the numerical parameters set forth in this 
specification and claims are approximations that can vary 
depending upon the desired properties sought to be obtained 
by the presently-disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia­
tions of in some embodiments ±50%, in some embodiments 
±40%, in some embodiments ±30%, in some embodiments 
±20%, in some embodiments ± 10%, in some embodiments 
±5%, in some embodiments ±1 %, in some embodiments 
±0.5%, and in some embodiments ±0.1 % from the specified 
amount, as such variations are appropriate to perform the 
disclosed method. 
10 example, those described herein. The permissible substitu­
ents can be one or more and the same or different for 
appropriate organic compounds. For purposes of this dis­
closure, cobalamin may comprise alkyl substituents and/or 
any permissible substituents of organic compounds 
15 described herein, including those that induce strain in the 
embodied compounds. This disclosure is not intended to be 
limited in any manner by the permissible substituents of 
organic compounds. 
Notably, throughout the present disclosure, various 
20 embodiments of the methods and compositions provided 
herein are described in the written examples and in the 
drawings. In these examples and drawings, some specific 
structures are labeled with numbers (e.g., 1, 2, 3, etc.) to 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 25 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
refer to the structures. For example, FIG. 8 includes distinct 
structures/compounds labeled as 31, 32, 33, 32, and 35, 
respectively. 
The presently-disclosed subject matter further includes 
pharmaceutical compositions comprising compounds as dis­
closed herein. Such pharmaceutical compositions may com-
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
With regard to alkyl substituents, the term "alkyl" refers 
30 prise at least one pharmaceutically-acceptable carrier. In this 
regard, the term "pharmaceutically acceptable carrier" refers 
to sterile aqueous or non-aqueous solutions, dispersions, 
suspensions or emulsions, as well as sterile powders for 
reconstitution into sterile injectable solutions or dispersions 
to alkyl groups with the general formula CnH2n+1 ' where n 
is in the range of about 1 to about 18 or more. The groups 
can be straight-chained or branched. Alkyl, when used 
herein, also comprises "lower alkyls," which refer to alkyl 
groups with the general formula CnH2n+i, where n is in the 
range of about 1 to about 6. In some embodiments, n is about 
35 just prior to use. Proper fluidity can be maintained, for 
example, by the use of coating materials such as lecithin, by 
the maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These composi­
tions can also contain adjuvants such as preservatives, 
40 wetting agents, emulsifying agents and dispersing agents. 
1 to about 3. Examples include methyl, ethyl, propyl, 
isopropyl, n-butyl, sec-butyl, t-butyl, isobutyl, n-pentyl, 
isopentyl, neopentyl, n-hexyl, and the like. Throughout the 
specification "alkyl" is generally used to refer to both 
unsubstituted alkyl groups and substituted alkyl groups, and 45 
this practice holds true for the other groups ( e.g., cycloalkyl, 
etc.) described herein. 
The term "aryl" as used herein is a group that contains any 
carbon-based aromatic group including, but not limited to, 
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, 50 
and the like. The term "aryl" also includes biaryls (e.g., 
naphthalene or biphenyl) or "heteroaryl," which is defined 
as a group that contains an aromatic group that has at least 
one heteroatom incorporated within the ring of the aromatic 
group. Examples of heteroatoms include, but are not limited 55 
to, nitrogen, oxygen, sulfur, and phosphorus. Likewise, the 
term "non-heteroaryl," which is also included in the term 
"aryl," defines a group that contains an aromatic group that 
does not contain a heteroatom. The aryl group can be 
substituted or unsubstituted. The aryl group can be substi- 60 
tuted with one or more groups including, but not limited to, 
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, alde­
hyde, amino, carboxylic acid, ester, ether, halide, hydroxy, 
ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described 65 
herein. The term "thiol" as used herein is represented by a 
formula -SH. 
Prevention of the action of microorganisms can be ensured 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic 
agents such as sugars, sodium chloride and the like. Pro­
longed absorption of the injectable pharmaceutical form can 
be brought about by the inclusion of agents, such as alumi­
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
polylactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro­
emulsions, which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo­
rating sterilizing agents in the form of sterile solid compo­
sitions which can be dissolved or dispersed in sterile water 
or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 
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suspensions, which can include suspending agents and 
thickening agents. Moreover, the compositions can take 
such forms as suspensions, solutions or emulsions in oily or 
aqueous vehicles, and can contain formulatory agents such 
as suspending, stabilizing and/or dispersing agents. Alter­
natively, the active ingredient can be in powder form for 
constitution with a suitable vehicle, e.g., sterile pyrogen-free 
water, before use. The formulations can be presented in 
unit-dose or multi-dose containers, for example sealed 
ampoules and vials, and can be stored in a frozen or 
freeze-dried (lyophilized) condition requiring only the addi­
tion of sterile liquid carrier immediately prior to use. 
The presently-disclosed subject matter further includes a 
kit that can include a compound or pharmaceutical compo­
sition as described herein, packaged together with a device 
useful for administration of the compound or composition. 
As will be recognized by those or ordinary skill in the art, 
the appropriate administration-aiding device will depend on 
the formulation of the compound or composition that is 
selected and/or the desired administration site/method. For 
example, if the formulation of the compound or composition 
is appropriate for injection in a subject, the device could be 
a syringe. For another example, if the desired administration 
site is cell culture media, the device could be a sterile 
pipette. 
Still further, the presently-disclosed subject matter 
includes a method for treating disease(s), such as cancer. In 
some embodiments, the method comprises administering a 
compound, including one of the compounds described 
herein, to an administration site of a subject in need thereof. 
The term "administering" refers to any method of pro­
viding a compound and/or pharmaceutical composition 
thereof to a subject. Such methods are well known to those 
skilled in the art and include, but are not limited to, oral 
administration, transdermal administration, administration 
by inhalation, nasal administration, topical administration, 
intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, and parenteral administration, including 
injectable such as intravenous administration, intra-arterial 
administration, intramuscular administration, and subcuta­
neous administration. Administration can be continuous or 
intermittent. In various aspects, a preparation can be admin­
istered therapeutically; that is, administered to treat an 
existing disease or condition (e.g., cancer, tumors, etc.). In 
further various aspects, a preparation can be administered 
prophylactically; that is, administered for prevention of a 
disease or condition. 
In some embodiments, a subject will be administered an 
effective amount of the compound. In this respect, the term 
"effective amount" refers to an amount that is sufficient to 
achieve the desired result or to have an effect on an unde­
sired condition. For example, a "therapeutically effective 
amount" refers to an amount that is sufficient to achieve the 
desired therapeutic result or to have an effect on undesired 
symptoms, but is generally insufficient to cause adverse side 
effects. The specific therapeutically effective dose level for 
any particular patient will depend upon a variety of factors 
including the disorder being treated and the severity of the 
disorder; the specific composition employed; the age, body 
weight, general health, sex and diet of the patient; the time 
of administration; the route of administration; the rate of 
excretion of the specific compound employed; the duration 
of the treatment; drugs used in combination or coincidental 
with the specific compound employed and like factors well 
known in the medical arts. For example, it is well within the 
skill of the art to start doses of a compound at levels lower 
10 
than those required to achieve the desired therapeutic effect 
and to gradually increase the dosage until the desired effect 
is achieved. If desired, the effective daily dose can be 
divided into multiple doses for purposes of administration. 
Consequently, single dose compositions can contain such 
amounts or submultiples thereof to make up the daily dose. 
The dosage can be adjusted by the individual physician in 
the event of any contraindications. Dosage can vary, and can 
be administered in one or more dose administrations daily, 
10 for one or several days. Guidance can be found in the 
literature for appropriate dosages for given classes of phar­
maceutical products. In further various aspects, a prepara­
tion can be administered in a "prophylactically effective 
amount"; that is, an amount effective for prevention of a 
15 disease or condition. 
Additionally, the terms "subject" or "subject in need 
thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi­
cal condition, disorder, or the like. The subject of the herein 
20 disclosed methods can be a vertebrate, such as a manmial, a 
fish, a bird, a reptile, or an amphibian. Thus, the subject of 
the herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
25 sex. Thus, adult and newborn subjects, as well as fetuses, 
whether male or female, are intended to be covered. A 
patient refers to a subject afflicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
The terms "treatment" or "treating" refer to the medical 
30 management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or 
disorder. This term includes active treatment, that is, treat­
ment directed specifically toward the improvement of a 
disease, pathological condition, or disorder, and also 
35 includes causal treatment, that is, treatment directed toward 
removal of the cause of the associated disease, pathological 
condition, or disorder. In addition, this term includes pal­
liative treatment, that is, treatment designed for the relief of 
symptoms rather than the curing of the disease, pathological 
40 condition, or disorder; preventative treatment, that is, treat­
ment directed to minimizing or partially or completely 
inhibiting the development of the associated disease, patho­
logical condition, or disorder; and supportive treatment, that 
is, treatment employed to supplement another specific 
45 therapy directed toward the improvement of the associated 
disease, pathological condition, or disorder. 
Moreover, in some embodiments, the present disclosure 
provides a novel chemoenzymatic alternative for the syn­
thesis of SAM and/or SeAM analogs. Certain embodiments 
50 of the subject matter of the present disclosure are related to 
methionine analog synthesis to provide substrates for a 
range of permissive methionine adenosyltransferases 
(MATs). Further embodiments of the present disclosure 
include analogs of S-adenosyl-1-methionine. Still further 
55 embodiments of the present disclosure include analogs of 
Se-adenosyl-L-methionine. And various embodiments of the 
present disclosure are advantageous at least because they 
circumvent liabilities of the existing state of the art. 
One embodiment of the subject matter of the present 
60 disclosure is a chemoenzymatic synthesis of SAM analogs 
and/or SeAM analogs. In some embodiments, the present 
disclosure provides methods of reacting S/Se-Met analogs 
with methyl transferases to produce SAM and/or SeAM 
analogs. In certain methods of the present disclosure, 2:about 
65 20% turnover from S/Se-Met analog(s) to SAM/SeAM 
analog(s) is achieved. And in other embodiments, 2:about 
10%, and/or 2:about 30%, and/or 2:about 40% and/or 2:about 
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50% turnover from S/Se-Met analog(s) to SAM and/or 
SeAM analog(s) is achieved in the presently disclosed 
methods. 
Embodiments of the subject matter of the present disclo­
sure also present the ability to directly couple SAM and/or 5 
SeAM synthesis with downstream MTase utilization in a 
one-pot reaction. As such, one embodiment of the subject 
matter of the present disclosure is a process using MAT to 
produce SAM and/or SeAM analogs. 
An additional advantage of this approach is the perme-
10 ability of cells to methionine, suggesting the novel potential 
for intracellular SAM and/or SeAM analog synthesis as 
enabling technology for a broad range of chemical and/or 
biological applications. 
In some embodiments, the present disclosure is directed 
to the synthesis of L-methionine and/or L-selenomethionine 15 
analogs, including non-natural and/or synthetic analogs, and 
to uses thereof. Indeed, in certain embodiments, the disclo­
sure provides compounds of the Formula II: 
(II) 
20 
12 
-continued
lx�N3, 
and X is selected from the group consisting of S and Se.
25 
wherein R1 is an alkyl group. In certain embodiments, R1 
comprises a propyl group, an ally! group, an aryl group 
and/or a propargyl group. Further, in some embodiments, R1 
30 
is chosen from: 
Ix� Ix� ls--c,
Ix�' Ix�' �N 
Ix�' Ix�' 
lx�· ls�,
35 
40 
45 
In some embodiments, R1 is selected from the group 
consisting of 
lx� s��(OOH
NH2 
NH2 IX�S�COOH, and lx� s�ccxm 
NH2 
wherein X is S. 
Additionally, the present disclosure is directed to the 
synthesis of cofactor analogs of S-adenosyl-L-methionine 
and/or Se-adenosyl-L-methionine using methionine adeno­
syltransferase, such as non-natural and/or synthetic analogs, !x�lx� 50 and to uses thereof. 
/X�NH,/S1
ls�·ls�N3 , 
ls�·lx�·
/xD /s�N,
55 
60 
65 
Accordingly, in some embodiments, the present disclo­
sure provides an S-adenosyl-L-methionine (SAM) and/or an 
Se-adenosyl-L-methionine (SeAM) analog of the Formula I: 
(I) 
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wherein R comprises a compound according to Formula II 
and wherein R is attached through an S or Se atom and/or 
through the X atom. And in certain embodiments, R com­
prises methionine-tetrazole. 
The present disclosure also provides, in certain embodi- 5 
ments, methods of producing a SAM analog and/or a SeAM 
analog, comprising at least the step of reacting a first 
substrate with a second substrate in the presence of a 
methionine adenosyltransferase (MAT). Additionally, the 
present disclosure provides, in some embodiments, methods 10 
of producing an indolocarbazole analog. Such methods 
comprise the step of reacting a first substrate with a second 
substrate in the presence of a methionine adenosyltrans­
ferase (MAT). 
In some embodiments, the first substrate comprises a 15 
compound according to Formula II, the second substrate 
comprises adenosine triphosphate (ATP) and/or the MAT 
comprises at least one of human MAT II catalytic alpha and 
regulatory beta subunit (hMAT2), human MAT II catalytic 
alpha subunit alone (hMAT2A), human MAT I catalytic 20 
subunit alpha (hMATlA), Escherichia coli MAT (eMAT), 
Sulfolobus solfataricus MAT (sMAT), and Methanocaldo­
coccus jannaschii MAT (mMAT). Additionally, the present 
disclosure provides that any of the methods described herein 
14 
alkylating the at least one drug, at least one molecule of 
DNA and/or at least one protein to produce a drug analog, 
a DNA analog and/or a protein analog in the vessel. 
And in certain embodiments, S-adenosyl-L-homocysteine 
hydrolase (SAH-hdyrolase) is provided in the vessel. It is 
believed that inclusion of SAH-hydrolase (SAHH) in the 
coupled reaction may prevent product inhibition associated 
with most if not all methyltransferases. 
In some embodiments, the present disclosure provides an 
S-adenosyl-L-methionine (SAM) or Se-adenosyl-L-methio­
nine (SeAM) analog of the Formula III: 
(III)
may be conducted one pot, i.e., a single vessel. The terms 25 wherein Xis selected from the group consisting of S and Se; 
"vessel", "pot" and "container" are used interchangeably in 
the present disclosure. 
The present disclosure further presents a method for 
production of a chemical library, the method comprising the 
step of reacting a plurality of compounds according to 30 
Formula II with ATP in the presence of at least one MAT to
obtain at least one synthesized compound. In some embodi­
ments, the at least one synthesized compound is a SAM 
analog and/or a SeAM analog. Furthermore, the present 
disclosure also provides, in certain embodiments, a method 35
of producing at least one SAM analog and/or at least one 
SeAM analog. The method comprises the step of reacting a 
first substrate comprising methionine-tetrazole with a sec­
ond substrate in the presence of at least one methionine 
adenosyltransferase (MAT). Moreover, in some embodi- 40 
ments, the second substrate comprises ATP and/or the MAT 
comprises at least one of human MAT II catalytic alpha and
regulatory beta subunit (hMAT2), human MAT II catalytic
alpha subunit alone (hMAT2A), human MAT I catalytic 
subunit alpha (hMATlA), Escherichia coli MAT (eMAT), 45
Sulfolobus solfataricus MAT (sMAT), and Methanocaldo­
coccus jannaschii MAT (mMAT). 
And in some embodiments, the present disclosure pro­
vides a method for producing a natural product analog,
comprising: (i) reacting a methionine analog and at least one 50
methionine adenosyltransferase to produce a SAM analog 
and/or a SeAM analog in a vessel; (ii) providing at least one 
methyl transferase and at least one natural product in the 
vessel; and (iii) alkylating the natural product in the pres­
ence of the methyl transferase and the SAM analog and/or 55 
the SeAM analog to produce a natural product analog in the 
vessel. In some embodiments, the methionine analog is a 
compound according to Formula II, as described herein­
above. 
Similarly, the present disclosure provides a method for 60 
alkylating at least one drug, at least one molecule of DNA 
and/or at least one protein, the method comprising (i) 
reacting a methionine analog and at least one methionine 
adenosyltransferase to produce a SAM analog and/or a 
SeAM analog in a vessel; (ii) providing at least one methyl 65 
transferase and at least one drug, at least one molecule of 
DNA and/or at least one protein in the vessel; and (iii) 
wherein, when X is S, R1 is selected from the group
consisting of:
�·�
·�C�, 
�N·�·�· 
+�·�· 
\(y. · � NH2, 
\(y' �· � N3, 
�·�·,P· 
�N;\u· 
�N;�. 
� 
1- V· and
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-continued
Y'Q N02; and 
wherein, when X 1s Se, R1 1s selected from the group 
consisting of: 
In some embodiments, the present disclosure provides an 
S-adenosyl-L-methionine analog of the Formula I:
N;:__N)l)--
w-
R 
OH OH 
(I) 
10 
40 
45 
50 
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(eMAT), Sulfolobus solfataricus MAT (sMAT), and Metha­
nocaldococcus jannaschii MAT (mMAT). 
In some embodiments of the methods of the present 
disclosure, the first substrate is a compound of the Formula 
II: 
(II) 
wherein R1 is selected from the group consisting of 
Ix� Ix� ls -c,.Ix� lx�lx� 
N, , lx�. lx�, ls�.lx"'Y 
Ix�, lx�NH2, 
ls1ls� 
ls�N,ls�
lx�lxD 
IS�N; l,u 
wherein R is a compound according to Formula II and R is 
attached through an S atom. 
In some embodiments, the present disclosure provides a 
method of producing an S-adenosyl-L-methionine analog or 
55 lx�N3, l se�NH2,
an S-adenosyl-L-methionine analog of the present disclo­
sure, comprising the step of reacting a first substrate com­
prising a methionine analog with a second substrate in the 60 
presence of a methionine adenosyltransferase (MAT). In 
some embodiments, the second substrate comprises adenos­
ine triphosphate (ATP), and in certain embodiments, the 
MAT comprises at least one of human MAT II catalytic 
alpha and regulatory beta subunit (hMAT2), human MAT II 65 
catalytic alpha subunit alone (hMAT2A), human MAT I 
catalytic subunit alpha (hMATlA), Escherichia coli MAT 
Is � 
IS� M<< 
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wherein X is selected from the group consisting of S and Se. 
Further, in some embodiments, the present disclosure 
provides a method of producing an indolocarbazole analog, 
comprising the step of reacting a first substrate comprising 
a methionine analog with a second substrate in the presence 
18 
10 and 
of a methionine adenosyltransferase (MAT), wherein the 15 
methionine analog is a compound of the Formula II: 
(II) 
wherein R1 is selected from the group consisting of 
/(� Ix� ls --c,. Ix� lx�lx� 
N, , lx�.lx�, ls�.IXI(· 
Ix�, lx�NH2,ls1ls� 
ls�N,ls�
lx�lxD 
IS�N; lxv 
and wherein X is selected from the group consisting of S and 
20 Se. In some embodiments, the second substrate comprises at
least one indolocarbazole group. And in some embodiments, 
the MAT comprises at least one of human MAT II catalytic 
alpha and regulatory beta subunit (hMAT2), human MAT II 
catalytic alpha subunit alone (hMAT2A), human MAT I 
25 catalytic subunit alpha (hMATlA), Escherichia coli MAT (eMAT), Sulfolobus solfataricus MAT (sMAT), and Metha­
nocaldococcus jannaschii MAT (mMAT). 
Moreover, in some embodiments, the present disclosure 
provides a method for producing a natural product analog, 
comprising: (i) reacting a methionine analog and at least one 
30 methionine adenosyltransferase to produce an S-adenosyl­
L-methionine analog and/or an Se-adenosyl-L-methionine 
analog of the present disclosure in a vessel; (ii) providing at 
least one methyl transferase and a natural product in the 
vessel; and (iii) alkylating the natural product in the pres-
35 ence of the methyl transferase and the S-adenosyl-L-me­
thionine analog and/or Se-adenosyl-L-methionine analog to 
produce a natural product analog in the vessel. In some 
embodiments of this method, the methionine analog is a 
compound of the Formula II: 
40 
45 
wherein R1 is selected from the group consisting of 50 
55 
60 
(II) 
lx�N3, lse�NH2, 65
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Ix�, lx�NH2, /s1/s� 
/s�N,/s� 
/x�/xD 
/S�N;/Xv 
lx�N3, /Se� NH2, /s� 
/s��·•
/xl)_ 
N02; 
and wherein X is selected from the group consisting of S and 
Se. 
The present disclosure profiles a range of MATs to iden­
tify MAT(s) that turn over a wide range of methionine 
analogs to the corresponding SAM and/or SeAM analogs. 
Further, the present disclosure demonstrates that a MAT 
reaction can be coupled in a single pot to generate differ­
ential alkylation. This enzymatic platform for differential 
alkylation (alkylrandomization) is an improvement over the 
existing prior art. 
As indicated herein, in some embodiments, the subject 
matter of the present disclosure is directed to the synthesis 
of differentially alkylated analogs. Another embodiment 
provides a process of combining a library of differentially­
alkylated analogs with a promiscuous methionine adenosyl­
transferase to afford the synthesis of differentially alkylated 
SAM and/or SeAM analogs. In certain embodiments, the 
present disclosure is directed to a method for producing a 
chemical library, comprising reacting a plurality of L-me­
thionine and/or L-selenomethionine analogs with ATP in the 
presence of at least one MAT to obtain a plurality of SAM 
and/or SeAM analogs. 
20 
differential alkylation of drugs and natural products. A 
further embodiment of the subject matter of the present 
disclosure provides differentially alkylated SAM and/or 
SeAM analogs. Yet another embodiment of the subject 
5 matter of the present disclosure provides SAM and/or SeAM 
analogs bearing reactive functional groups as reagents for 
cell biology/epigenetics. 
And a further embodiment of the subject matter of the 
present disclosure is the process of feeding said analogs 
10 (bearing reactive functional groups) to afford the above in a 
cell-based format (versus crude extracts which is the current 
state of the art). Additionally, the subject matter of the 
present disclosure provides a platform for MAT engineering 
and evolution, a coupled MAT-MTase platform for natural 
15 product alkylrandomization, and a platform for MTase engi­
neering and evolution. 
One of ordinary skill in the art would readily recognize 
that embodiments of the subject matter of the present 
disclosure provide robust combinatorial methods for the 
20 synthesis of methionine analogs. 
25 
Moreover, the ability to couple SAM synthesis and utili­
zation in a single vessel circumvents issues associated with 
rapid SAM analog decomposition. 
EXAMPLES 
The presently-disclosed subject matter is further illus­
trated by the following specific but non-limiting examples. 
The examples may include compilations of data that are 
30 representative of data gathered at various times during the 
course of development and experimentation related to the 
presently-disclosed subject matter. 
35 
Example I 
Chemoenzymatic Synthesis of SAM Analogs: 
This example highlights a broadly applicable platform for 
the syntheses of SAM analogs that is directly compatible 
with downstream SAM utilizing enzymes. The ability to 
40 couple SAM synthesis and utilization in a single vessel 
circumvents issues associated with rapid SAM analog 
decomposition and thereby opens the door to the further 
interrogation of a wide range of SAM utilizing enzymes. As 
a proof of concept for the feasibility of natural product 
45 'alkylrandomization', the coupled strategy was used to gen­
erate a small set of indolocarbazole analogs in conjunction 
with the rebeccamycin 0-methyltransferase RebM. 
Enzyme-catalyzed late stage group transfer-based tailor­
ing reactions contribute to the structural and functional 
50 diversity of many complex natural products (NPs).[1] Rep­
resentative examples include amination, acylation, alky­
lation, glycosylation, halogenation, phosphorylation and 
sulfation and, in some cases, enzymes responsible for such 
transformations display notable flexibility with respect to 
55 their substrate scope. [2] Such promiscuity is an enabling 
feature of chemoenzymatic NP diversification platforms as 
exemplified by NP glycorandomization (a platform for dif­
ferential glycosylation of natural products/drugs). [3] Among 
the examples above, enzyme-catalyzed alkylation is a highly 
60 prevalent occurrence that leads to NP N-, 0-, S- and/or 
C-alkylation (FIG. 2).[4] Thus, a platform to co-opt natural
product methyltransferases (MTs) for broad natural product
differential alkylation (alkylrandomization) will dramati-
cally expand the potential scope of NP chemical diversity.
Another embodiment of the subject matter of the present 65 
disclosure is a process of the compounds of the present 
disclosure with promiscuous methyltransferases to afford 
The typical alkyl donor for MT-catalyzed alkylation is 
S-adenosyl-L-methionine (SAM) and importantly, the pres­
ent inventors have demonstrated NP [5], protein, [6] and
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nucleic acid [7] MTs to transfer alternative alkyl groups in 
the presence of suitably modified SAM analogs. However, 
reminiscent of the restriction imposed upon glycorandom­
ization by sugar nucleotide availability, access to stable 
SAM analog arrays similarly restricts NP alkylrandomiza- 5 
tion development. 
Current state-of-art for SAM analog chemical synthesis 
relies upon multi-step syntheses of diastereomeric SAM 
analog mixtures and requires HPLC purification to remove 
starting material, S-adenosyl-homocysteine (SAH, a strong 10 
inhibitor of MTs). [8] The desired purified SAM analogs 
from this process are also markedly unstable, thereby lim­
iting their practical development as standalone synthetic 
reagents and/or biological probes. Within this context, a 
general platform to enable the generation and direct utiliza- 15 
tion of SAM analogs, beginning from stable precursors, 
would be considered advantageous. 
To address this need, herein a broad substrate specificity 
assessment of a representative set of five distinct methionine 
adenosyltransferases (MATs) from various sources is 20 
described. MAT (EC 2.5.1.6; also sometimes referred to as 
Ado Met synthetase or SAM synthetase) is the primary 
catalyst used for the biosynthesis of SAM from adenine 
triphosphate (ATP) and L-methionine (Met) (FIG. 1, FIG. 2) 
and there is preliminary evidence to suggest certain MATs to 25 
be capable of Met analog utilization. [6e, 9] Consistent with 
this notion, the studies highlighted herein reveal human 
22 
MAT II (hMAT2) to enable the cumulative synthesis of a 
broad panel ofunnatural SAM analogs (29 analogs detected) 
starting from synthetic S/Se-alkylated Met analogs (44 ana­
logs) or commercial sources (3 analogs). 
To demonstrate the feasibility of NP alkylrandomization, 
this study also highlights the subsequent generation of a 
small set of indolocarbazole analogs using a coupled 
hMAT2-RebM system, where RebM is the sugar C4'-0-MT 
involved in rebeccamycin biosynthesis. [5a, 10] This study 
offers both a strategic advance in terms of NP diversification 
and reveals hMAT2 to display surprising permissivity. 
Given the conflicting reports regarding the relative sta­
bility of S- versus Se-SAM [ 6c, 6d, 11] and the fact that 
Se-SAM is considered a better alkyl donor than S-SAM in 
MT-catalyzed reactions due to the inherently longer and 
weaker Se----C bond, [11 b] both S- and Se-Met analogs were 
synthesized for this study. The general strategy for the 
synthesis of the S- and Se-Met analog panel employed direct 
or reductive alkylation of the corresponding L-homocysteine 
dimer (1 or 1-Se, FIG. 4 i and iii, respectively), L-Hcy (FIG. 
4, ii) or 2-Se (FIG. 4, iv) following modifications of reported 
strategies. [12] The desired S- and Se-Met analogs were 
purified from crude reaction mixtures by reverse phase high 
pressure liquid chromatography (RP-HPLC), C18 RP flash 
chromatography or Dowex 50W8X-200 resin to afford iso­
lated yields ranging from 20-90% (see Table 1). 
TABLE 1 
Code 
1, 1-Se 
2, 2-Se 
3, 3-Se 
4, 4-Se 
6, 6-Se 
7, 7-Se 
Swnmary of synthesized L-methionine and L-selenomethionine analogs 
Compound 
/
x
,, X
�
COOH 
NH2 
NH2 
HOOC� X / 
Method 
S-alkyl Se-alkyl Code 
c.a.[a] ref [25] 16 
c.a. [a] c.a. [a] 17 
FIG. 10 FIG. 12 18 
FIG. 10 FIG. 12 19, 19-Se 
FIG. 10 n.a.[bJ 20, 20-Se 
FIG. 11 FIG. 13 21 
FIG. 11 FIG. 12 22, 22-Se 
Compound 
ls� N3 
Is� 
Ix� 
1xD 
1S� N3 
Method 
S-alkyl Se-alkyl 
FIG. 10 n.a.[b] 
FIG. 10 n.a.[bJ 
FIG. 10 n.a.[bJ 
FIG. 10 FIG. 13 
FIG. 11 FIG. 13 
FIG. 10 n.a.[bJ 
FIG. 10 FIG. 14 
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TABLE I-continued 
Summary of synthesized L-methionine and L-selenomethionine analogs 
Code Compound 
8, 8-Se 
9, 9-Se 
10, 10-Se 
11 Is� 
12, 12-Se 
;(� 
13, 13-Se 
Ix� 
14 
15, 15-Se 
[ale.a.: commercially available; 
[bln.a.: not available. 
Method 
S-alkyl Se-alkyl Code 
FIG. 10 FIG. 13 23, 23-Se 
FIG. 10 FIG. 14 24-Se 
FIG. 10 FIG. 13 25 
FIG. 10 n.a.[bJ 26 
FIG. 10 FIG. 12 27, 27-Se 
FIG. 10 FIG. 13 28 
FIG. 10 n.a.[bJ 29 
FIG. 10 FIG. 13 30 
A representative set of MATs from variant sources, 
including bacterial, archaeal and manmialian orthologs, 
were selected for the initial assessment. Specifically, the 
exploratory set included human MAT II catalytic alpha and 
regulatory beta subunit (hMAT2), [13] human MAT II 
catalytic alpha subunit alone (hMAT2A), [13] human MAT 
I catalytic subunit alpha (hMATlA),[13] Escherichia coli 
MAT (eMAT),[14] and the thermophilic Methanocaldococ­
cus jannaschii MAT (mMAT). [15] The basis for inclusion 
of the human homo logs derives from an interest to interro­
gate the substrate specificities of disease-relevant hMATs, 
[16] while the additional bacterial and archaeal homologs
were selected to compare and contrast the current study with
prior work relating to their substrate specificities.[9a, 17]
Compound 
Is� 
Is� 
!x�No,
ls � s'v-"'(OOH 
NH2 
NH2 ls�s�COOH
Method 
S-alkyl Se-alkyl 
FIG. 10 FIG. 12 
n.a.[bJ FIG. 13 
FIG. 10 n.a.[bJ 
FIG. 10 n.a.[bJ 
FIG. 11 FIG. 13 
FIG. 10 n.a.[bJ 
FIG. 10 n.a.[bJ 
FIG. 10 n.a.[bJ 
Standard uniform assay conditions (2 mM Met analog, 1 
mM ATP, 5 µM MAT, 25 mM Tris, 5 mM MgCl2, 50 mM 55 KC!, pH 8, 4 h) were adopted to facilitate this broad 
assessment. For the thermophilic counterpart (mMAT), reac­
tions were conducted at 65° C., while all other reactions 
were incubated at 37° C. Production of SAM analogs was 
60 determined by an RP-HPLC end point assay to afford 
complete analysis of the desired SAM analog and/or any 
corresponding degradation products known to directly 
derive from the desired SAM analog intermediate. Putative 
SAM analog and SAM-derived degradative product forma-
65 tion was subsequently confirmed via high-resolution mass 
spectrometry (HRMS) analysis for all positive reactions (see 
Table 2). 
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TABLE 2 
Surnm of MAT reactions 
Percentage Turn-over H. R. Mass (m/z) 
Analog eMAT hMATlA hMAT2A hMAT2 mMAT Theoretical Observed 
2 90 95 100 100 100 399.1445, 297.0896[a]399_1444, 298.0965[b] 
2-Se 100 100 100 100 100 447.0890, 345_034o[a]447_0895, 346.0416[b] 
3 75 90 88 94 413.1602, 311.1052[a]413.1599, 312.1121 [b] 
3-Se 57 53 82 73 461.1046, 359.0497[a]416.1040, 360.0565[b] 
4 2 2 20 321.0896[a] 322.1051[b] 
4-Se 0 7 44 58 14 369.0340[a] 370.0411 [b] 
6 2 2 13 20 322.0848[a] 323.0919[b] 
6-Se 2 4 23 33 0 370.0293[a] 371.0371 [b] 
7 2 50 52 16 425.1602, 323.1052[aJ425.1609, 324.1129[b] 
7-Se 2 10 42 59 15 371.0497[a] 372.0568[b] 
8 2 54 55 21 427.1758, 325.1209[a]427.1759, 326.1281 [b] 
8-Se 0 24 74 27 475.1203, 373.0653[a]475_1200, 374.0726[b] 
9 0 2 2 2 427.1758, 325.1209[a]427_ l 762, 326.1282[b] 
9-Se 11 10 10 373.0653[a] 374_0743[b] 
10 0 0 12 40 16 437.1602, 335.1052[a]437_1599, 336.1124[b] 
10-Se 2 22 55 17 383.0497[a] 384.0566[b] 
11 2 2 25 30 439.1758, 337.1209[a]439_ l 754, 338.1275[b] 
12 0 0 2 2 439.1758, 337.1209[a]439_ l 754, 338.1282[b] 
12-Se 11 12 14 385.0653[a] 386.0730[b] 
13 0 0 12 13 12 441.1915, 339.1365[a]441.1966, 340.1477[b] 
13-Se 0 26 49 32 489.1359, 387.081Q[a]489.1358, 388.0882[b] 
14 0 0 0 0 441.1915, 339.1365[aJ441.1918, 340.1439[b] 
16 4 2 4 44 451.1758 451.1756 
17 0 4 18 49 29 454.1616, 352.1066[a]454_1615, 353.1140[b] 
18 0 0 0 0 455.2071, 353.1522[a]455.2123, 354.1634[b] 
19 0 4 13 453.1915 453.2044 
19-Se 9 15 16 399.0810[aJ 400.0878[b] 
21 0 0 19 46 31 468.1772, 366.1223[a]468.1772, 367.1296[b] 
23 0 2 12 32 480.1772, 378.1223[a]480.1768, 379.1292[b] 
23-Se 4 9 15 18 426.0667[a] 427.0687[b] 
24-Se 7 16 25 30 400.0762[a] 401.0830[b] 
[altheoretical mass of degraded 5'-alkyl-thio(seleno)-5'-deoxyadenosine (MTA); observed mass of degraded 5'-alkyl-thio(seleno)-
5'-deoxyadenosine (MTA): 
[bl[M+H] 
A cumulative comparison of the substrate specificity for 
all five MAT model systems based upon RP-HPLC is 
illustrated in FIG. 5 and FIG. 6 wherein observed 5'-methyl­
thio(seleno)-5'-deoxyadenosine (MTA) production (via RP­
HPLC) was interpreted as product based upon the well­
established SAM decay pathways indicating MTA to 
directly derive from SAM (not ATP). [6d, lla, 18] This 
cumulative analysis revealed hMAT2 to be the most per­
missive of the MATs tested at 37° C., while the thermophilic 
mMAT also displayed notable permissivity at 65° C. Of the 
4 7  putative substrates tested with hMAT2, 10 led to appre­
ciable (>50%) SAM analog production, an additional 8 led 
to moderate (25-50%) conversion, while 11 offered detect­
able product ( <25%) under the conditions described. In 
general, smaller alkyl substitutions were better tolerated, 
suggesting steric infringement to possibly prohibit larger 
substitutions. Interestingly, in the case where direct com­
parisons could be made, the degree of unsaturation corre-
medium (mMAT) or stringent (eMAT and hMATlA) sub­
strate specificities. Superimposition of available X-ray struc­
tures (hMATlA, hMAT2A and eMAT) reveal a root mean 
40 square deviation (rmsd) of 0.268 A between hMAT2A and 
hMATlA (sequence identity of -85%) and -0.56 A between 
eMAT and hMATlA or hMAT2A (sequence identity of 
-58%). Structural comparison of the permissive (hMAT2A)
and stringent (hMATlA and eMAT) MATs highlights key
45 distinctions among residues (FIG. 7). Interestingly, while 
hMAT2A active site mutagenesis has led to a slight improve­
ment in turnover with an unnatural analog, [ 6e] the current 
structural comparison suggests the broad substrate specific­
ity of hMAT2A to be predominately mediated by residues 
50 within the secondary shell and/or on the solvent-exposed 
surface distal to active-site loops that likely contribute to 
interdomain movement/dynamics. Whether or not these resi­
dues contribute to the hMAT2 alpha/beta interface is cur-
rently unknown. 
lated with a reduction in turnover (e.g., 55 To subsequently assess the feasibility of 'alkylrandom-
propyl>allyl>propargyl). Also, in most cases, Se-analogs 
were preferred over their S-comparators, most notably for 
hMAT2. Consistent with previous studies, [19] the regula­
tory beta subunit of MAT2A improved the overall profi­
ciency of hMAT2 and, in some cases, this increase in 
proficiency translated to a slight increase in permissivity in 
the current study. Finally, the addition of inorganic pyro­
phosphatase in an attempt to drive the reaction via degra­
dation of the pyrophosphate co-product did not appreciably 
increase turnover. 
Based on these results, the corresponding MATs can be 
generally classified as having broad (hMAT2/hMAT2A), 
ization' via a single vessel coupled MAT/MT reaction, the 
rebeccamycin MT RebM was selected as the representative 
methyl transferase (MT). RebM is the sugar C4'-0-MT 
involved in rebeccamycin biosynthesis and has previously 
60 been demonstrated to tolerate both alternative acceptors and 
alkyl donors. [5a, 10] The coupled system also employed 
standard assay conditions (2 mM Met analog, 1 mM ATP, 50 
µMrebeccamycin congener compound31, 5 µMhMAT2, 10 
µM RebM, 5 µM SAH-hydrolase, 25 mM Tris, 5 mM 
65 MgCl2, 50 mM KC!, pH 8, 24 h at 37
° C.) and included only 
S/Se-Met analogs that afforded ;;,;20% turnover with hMAT2 
under standard conditions (FIG. 5, FIG. 6). From this pilot 
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study, 8 out of 18 of the selected S/Se-Met series led to the 
production of the corresponding differentially alkylated 
indolocarbazoles in appreciable yields (;;,;40%, FIG. 8 and 
FIG. 15). Importantly, inclusion of SAH-hydrolase (SAHH) 
in the coupled reaction, to prevent product inhibition asso- 5 
ciated with most if not all MTs, [20] improved overall 
product yields by 15-40%. Notably, this is the first report of 
MT-catalyzed acetonitrilylation (See FIG. 8, compound 35 
deriving from L-Met analog 6 or 6-Se). 
In conclusion, the broad substrate specificity analysis 10 
presented revealed hMAT2/2A and mMAT to display nota­
bly broad substrate tolerance. Of these, hMAT2A is over­
expressed in a number of tumor types, [21] where inhibition 
of hMAT2A by small molecule inhibitors or siRNA affords 
dramatic tumor reduction. [22] The discovered substrate 15 
malleability of hMAT2A in conjunction with aberrant can­
cer-specific hMAT2A overexpression therefore may offer 
the potential to employ suitable S/Se-Met analogs as cell­
based metabolic probes of the role of methylation in cancer. 
In addition, the work highlighted herein enables one of the 20 
first the facile syntheses of SAM analogs directly compatible 
with downstream SAM utilizing enzymes including MTs 
and is advantageous over other recently reported chemoen­
zymatic strategies that depend upon synthetic non-native 
alkylated amino acid alkyl donors and nucleoside acceptors. 25 
As such, this platform circumvents a major liability of 
prior SAM analog/MT strategies, namely SAM analog 
decomposition, and thereby opens the door to the further 
interrogation of a host of MTs which operate upon macro­
molecular (protein/nucleic acid) and small molecule (natural 30 
products) substrates. Finally, the strategy presented unveils 
a single vessel proof of concept for natural product 'alkyl­
randomization' which, while currently somewhat limited via 
enzyme specificity, is expected to be further advanced via 
MT/MAT directed evolution and/or structure-based engi- 35 
neering in a manner reminiscent to that used for advancing 
glycorandomization. [3, 23] 
Materials and Methods 
Unless otherwise stated, all general chemicals and 
reagents were purchased from Sigma-Aldrich (St. Louis, 40 
Mo., USA) or Acros (New Jersey, USA) and were reagent 
grade or better. L-homocystine was purchased from Bachem 
(Torrance, Calif., USA). L-homocystine [24] and L-seleno­
homocysteine [25] were synthesized following previously 
published protocols. E. coli BL21(DE3) competent cells 45 
were purchased from Invitrogen (Carlsbad, Calif.). The 
pET28a E. coli expression vector was purchased from 
Novagen (Madison, Wis.). Primers were purchased from 
Integrated DNA Technology (Coralville, Iowa). Pfu DNA 
polymerase was purchased from Stratagene (La Jolla, 50 
Calif.). Restriction enzymes and T4 DNA ligase were pur­
chased from New England Biolabs (Ipswich, Mass.). PD-10 
colunm and Ni-NTA superflow columns were purchased 
from GE Healthcare (Piscataway, N.J.). 
High-resolution mass spectrometric data were obtained 55 
using a Waters (Milford, Mass.) LCT time-of-flight spec­
trometer for electrospray ionization (ESI) or AB SCIEX 
TripleTOF® 5600 System. NMR spectra were obtained on 
Varian Unity Inova 400 or 500 MHz instruments (Palo Alto, 
Calif.) at the NMR facility of College of Pharmacy at 60 
University of Kentucky using 99.8% CDC13 with 0.05% v/v 
TMS, 99.8% CD30D or 99.8% D20 from Cambridge Iso­
topes (Cambridge Isotope Laboratories, MA, USA). 1H and 
13C chemical shifts were referenced to internal solvent 
resonances. Multiplicities are indicated by s (singlet), d 65 
(doublet), t (triplet), q (quartet), quin (quintet), m (multi­
plet), and br (broad). Chemical shifts are reported in parts 
28 
per million (ppm) and coupling constants J are given in Hz. 
Routine 13C NMR spectra were fully decoupled by broad­
broad WALTZ decoupling. All NMR spectra were recorded 
at ambient temperature. 
Normal-phase flash chromatography was performed on 
40-63 µm, 60 A silica gel (from Silicycle, Quebec, Canada).
Analytical TLC was performed on silica gel glass TLC
plates (from EMD chemical Inc). Visualization was accom­
plished with UV light (254 nm) followed by staining with
dilute sulfuric acid (5% in ethanol) solution or 10% ninhy­
drin in ethanol and heating. High performance liquid chro­
matography (HPLC) was accomplished using an Agilent
1260 system equipped with a diode array detector (DAD).
Method A (HPLC): 
Analytical reverse-phase (RP) HPLC was conducted with 
a Luna C-18 (5 µm, 4.6 mmx250 mm) column (Phenom­
enex, Torrance, Calif., USA) [gradient of 1 % B to 40% B 
over 22 min, 55% B to 100% B over 3 min, 100% B for 6 
min, 100% B to 5% B over 1 min, 5% B for 3 min 
(A=ddH20 with 0.1% TFA; B=acetonitrile) flow rate=l mL 
min-1 ; A218]. The reaction was monitored by the retention 
time difference between starting material and product. 
Method B (HPLC): 
Semi-preparative RP HPLC was conducted on a Gemini 
C18 (5 µm, 10x250 mm; Phenomenex, Torrance, Calif., 
USA) colunm to purify the methionine analogs [gradient of 
5% B to 55% B over 25 min, 55% B to 100% B over 2 min, 
100% B for 6 min, 100% B to 5% B over 1 min, 5% B for 
4 min (A=ddH20 with 0.1% TFA; B=acetonitrile) flow 
rate=4.5 mL mind; A218]. 
Method C (Flash Chromatography): 
Pilot reversed-phase purification was conducted by flash 
column chromatography using an Alltech C18 Extract-Clean 
column (10,000 mg, 75 mL, Alltech Associates, Deerfield, 
Ill., USA) for the scale-up purification of methionine ana­
logs. The column was pre-equilibrated with ddH20/0.1 % 
TFA and after loading the solid crude material, a gradient of 
100/0 to 60/40 water:acetonitrile containing 0.1% TFA was 
used as the mobile phase. Eluted fractions were checked by 
TLC (15:1:84 MeOH/NH40H/CHCl3, ninhydrin stain) and 
confirmed via analytical HPLC (Method A) to identify 
product fractions. 
Method D (HPLC): 
To monitor MAT reactions, analytical RP HPLC 
employed a Luna C18 colunm (5 µm, 4.6 mmx250 mm; 
Phenomenex, Torrance, Calif., USA) [gradient of 10% B to 
40% B over 15 min, 40% B to 75% B over 5 min (A=lO mM 
NaH2P04, 5 mM octane sulfonic acid, pH was adjusted to 
3.5 using phosphoric acid; B=acetonitrile) flow rate=l mL 
min-1; A254]. 
Method E (HPLC): 
To monitor the coupled hMAT2/RebM reactions, analyti­
cal RP HPLC was conducted with a Luna C18 colunm (5 µm, 
4.6 mmx250 mm; Phenomenex, Torrance, Calif., USA) 
[gradient of 10% B to 100% B over 20 min (A=ddH20 with 
0.1% TFA; B=acetonitrile) flow rate=l mL min-1 ; A315]. 
The sequence of MATs involved in this study can be 
found within the National Center for Biotechnology Infor­
mation (NCBI) Protein database and include: Homo sapiens 
MAT2A (hMAT2A; genebank accession number 
AAH01686.1); Homo sapiens MATlA (hMATlA, genebank 
accession number AAQ89058.1); Homo sapiens MAT II 
(co-expression of MAT2A with MAT2B; genebank acces­
sion number AAH01686.1); Escherichia coli MAT (eMAT; 
genebank accession number AAG58073.1); and Methano­
caldococcus jannaschii (mMAT; genebank accession num­
ber Q58605.1). 
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All DNA sequencing was conducted by the University of 
Wisconsin Biotechnology Center with the primers T7 pro­
moter. All Luria-Bertani (LB) media and agar were supple­
mented with 35 µg mL-1 kanamycin. High-throughput assay
absorbance readings were conducted using a FLUOstar 5 
Omega plate reader (BMG Labtechnologies, Cary, N.C., 
USA). HPLC peak areas were integrated with Star Chro­
matography Workstation Software (Varian, Palo Alto, Calif., 
USA) and the percent conversion calculated as a percent of 
the total peak area. High resolution electrospray ionization 10 
(ESI) mass spectra were recorded on a AB Sci ex Triple TOF 
5600 instrument coupled with an Eksigent Ekspert micro LC 
200 system with source temperature of 150° C., ion spray 
voltage floating (ISVF) of 5000 V in positive mode. Samples 
were infused at 20 µL min-1 and spectra collected for 3 min 15 
at a resolution greater than 31000. In negative mode ISVF 
30 
3 by the addition of 1 M HCI, centrifuged and subsequently 
purified by semi-preparative HPLC (Method B) to ulti­
mately afford the desired S-alkylated L-methionine analogs 
in 20%-60% yield. 
General Procedure for the Na/NH3 Reduction & Alky­
lation of L-Selenohomocystine 
(FIG. 11, used for compounds 3-Se, 4-Se, 7-Se, 12-Se and 
23-Se). L-Selenohomocystine[s2J (100 mg, 0.27 mmol) was
treated in manner identical to that described in the section 
labeled "general procedure for the Na/NH3 reduction & 
S-alkylation of L-homocysteine" to provide the desired Se-
alkylated L-selenomethionine analogs in yields ranging from
16%-85% yield.
General procedure for NaBH4 reduction & Se-alkylation 
of L-selenohomocystine 
(FIG. 13, used for compounds 6-Se, 8-Se, 10-Se, 13-Se, 
15-Se, 19-Se, 20-Se, 24-Se, 27-Se). According to a proce­
dure from Zhang et al., [26] to the THF solution of L-sele­
nohomocystine[s2J (100 mg, 0.276 mmol) in a small flask
of -4000 V was used. Cl 7 lysophosphatidyl choline with a 
mass of 510.3554 and Cl 7 lysophosphatidic acid with a 
mass of 423.2517 were used as internal references to cali­
brate the spectra in positive and negative modes respec­
tively. 
General Procedure of for Azido Installation 
(FIG. 9, used for compounds 17, 21, 23, 23-Se, 28, 29 and 
30). Dibromo-alkane (1.0 g, 1.0 eq) was dissolved in 20 mL 
CH2Cl2 and to this was added nBu4NHS04 (0.5 eq) and 
NaN3 (0.8 eq) under stirring. A 20 mL sat. NaHC03 solution 
was subsequently added and the reaction was stirred vigor­
ously for 2 h. The organic layer was washed with water and 
brine (20 mL each) and then dried over Na2S04. After the 
CH2Cl2 solvent was concentrated in vacuo carefully, the 
product was used directly as a monobromo or dibromo 
mixture without further purification for the alkylation reac­
tion. 
20 was added alkyl bromide (4.0 eq) under N2 with stirring at 
room temperature. NaBH4 (83.5 mg, 2.21 mmol, 8 eq) was 
dissolved in 0.12 M NaOH/water, and this solution was 
introduced to the reaction flask drop-wise via syringe. The 
reaction was subsequently stirred under N2 at room tem-
General Procedure for the Na/NH3 Reduction & S-Alky­
lation of L-Homocystine 
25 perature for 5 h and then adjusted to pH 5-7 by addition of 
1 M HCI. The solvent was removed completely under 
reduced pressure and the residue was dried. A portion (10 
mg) of the dried residue was dissolved with 400 µL H20 
with 0.1% TFA, adjusted to pH 3 by addition of 1 M HCI, 
30 centrifuged and the supernatant was purified by preparative 
HPLC (Method B) to provide the desired Se-alkylated 
L-selenomethionine analogs in yields ranging from 18%-
99% yield.
General Procedure for the Demethylation & Se-Alky-
35 lation of L-Selenomethionine 
(FIG. 14, used for compounds 9-Se, 22-Se). According to 
a procedure from Dekker, et al, [27] L-selenomethionine 
(100 mg, 0.51 mmol) was dissolved in 5 mL of concentrated 
HCI and to this was added the corresponding alkyl bromide 
40 (5.0 eq). The reaction was refluxed at 100° C. for 12 h. The 
reaction was then allowed to cool down to room tempera­
ture, diluted with water (10 mL), and adjusted with 30% 
NH40H to pH=7. The solvent was concentrated under 
reduced pressure to less than 1 mL, frozen at -80° C., and 
(FIG. 10, used for compounds 3, 4, 5, 8-19, 21-23, 25, 26 
and 28-30). L,L-homocystine (100 mg, 0.37 mmol) (from 
Bachem, Torrance, Calif., USA) was added to 20 mL liquid 
ammonia at -78° C. and stirred until fully dissolved. Small 
fragments of sodium metal (34 mg, 1.5 mmol) were added 
until a deep blue color persisted for at least 1 min. The 
corresponding alkyl bromide (2.0 eq) was then introduced, 
which caused the blue solution to quickly proceed to a 
mixture with a white precipitate. Ammonium chloride (20 
mg, 0.37 mmol) was then added to the reaction and the 
reaction was immediately removed from the cooling bath. 
The reaction flask was left open to the atmosphere at 
ambient temperature to allow ammonia to evaporate. The 
resulting residue was dissolved in 5 mL deionized water and 
the pH was adjusted to pH 5-7 by the addition of 1 M HCI. 50 
The solvent was removed under reduced pressure and the 
residue was dried. A fraction (10 mg) of the dried residue 
was dissolved with 400 µL dH20 with 0.1 % TFA, adjusted 
45 lyophilized to form a dry powder. The powder was purified 
by reversed-phase flash chromatography (Method C), to 
give 9-Se (9% yield) and 22-Se (7% yield). 
Example 
(2S)-2-amino-4-( ethylsulfanyl)butanoic acid 
( compound 3) 
to pH 3 by the addition of 1 M HCI, centrifuged and 
subsequently purified by semi-preparative HPLC (Method 55 
B) to ultimately afford the desired S-alkylated L-methionine
analogs in 22%-99% yield.
Some modifications of the strategy illustrated in FIG. 10 
were employed for the synthesis of compound 3. Specifi­
cally, the dried residue after completion of the L-homocys­
tine (250 mg, 0.932 mmol)/iodoethane (165 µL, 2.04 mmol) 
and subsequent evaporation of NH3 was dissolved in ddH20 
(30 mL) and solid NaOH (1.20 g, 0.03 mo!) was added, 
General Procedure for the S-Alkylation of L-Homocyste­
me 
(FIG. 11, used for compounds 6, 7, 20 and 27). L-homo­
cysteine[SIJ (10 mg, 0.07 mmol) was dissolved in 1 mL 
acetone and to this was added the corresponding alkyl 
bromide (2.0 eq) and K2C03 (20 mg, 0.14 mmol). The 
reaction was stirred under room temperature until HPLC 
indicated the completion of the reaction (Method A). The 
solvent was removed in vacuo, the resulting residue was 
dissolved in 400 µL dH20 with 0.1% TFA, adjusted to pH 
60 creating a 1 M sodium hydroxide solution. After stirring for 
1 h, the basic solution was slowly loaded onto a Dowex 
50W8X-200 2.5 cmx3 cm colunm prequilibrated with 
ddH20. The colunm was washed with several colunm vol­
umes of ddH20 and the product subsequently eluted with 
65 2.5% aqueous NH40H. The fractions, identified by TLC 
(15:1:84 MeOH/NH40H/CHCl3, ninhydrin stain), were 
combined and lyophilized to a white amorphous solid (184 
US 9,879,043 Bl 
31 32 
mg, 61% yield). 1H NMR (DMSO-d6/TFA-d1=20/1, 500 
MHz) Ii 4.01 (t, 1=6.2 Hz, lH), 2.48-2.64 (m, 2H), 2.49 (q, 
1=7.3 Hz, 2H), 2.00 (m, 2H), 1.17 (t, 1=7.3 Hz, 3H); 13C 
NMR (DMSO-diTFA-d1=20/1, 125 MHz) Ii 175.9, 56.3, 
35.4, 31.4, 30.0, 20.1; HRESI calculated for C6H14N02S 5 
([M+Hr) m/z 164.0740; measured m/z 164.0744. 
1=6.5H, lH), 3.46 (s, 2H), 2.80 (t, 1=11.5 Hz, 2H), 1.98-2.27 
(m, 2H); 13C NMR (D20, 125 MHz) Ii 171.4, 118.5, 51.4, 
29.0, 27.3, 16.1; HRESI calculated for C6H11N202S ([M+ 
Hr) m/z 175.0536; measured m/z 175.0534. 
Example 
Example 
(2S)-2-amino-4-( ethylselanyl)butanoic acid ( com­
pound 3-Se) 
FIG. 12 with bromoethane yielded compound 3-Se (4.1 
mg, 85% yield) as a white solid. 1H NMR (D20, 400 MHz) 
Ii 3.85 (t, 1=6.2 Hz, lH), 2.43-2.50 (m, 4H), 2.01-2.11 (m, 
2H), 1.19 (t, 1=7.6 Hz, 3H); 13C NMR (D20, 100 MHz) Ii
172.6, 53.5, 30.8, 17.0, 16.8, 14.7; HRESI calculated for 
C6H14N02Se ([M+Hr) m/z 212.0184; measured m/z 
212.0187. 
Example 
(2S)-2-amino-4-(prop-2-yn-1-ylsulfanyl)butanoic 
acid ( compound 4) 
FIG. 10 with propargyl bromide yielded compound 4 (4.5 
mg, 75% yield) as a white solid together with compound 5 
(0.3 mg) as a white oil. 1H NMR (D20/TFA=20/1, 400 
MHz) ll 4.09 (t, 1=6.4 Hz, lH), 3.24 (d, 1=2.8 Hz, 2H), 2.74
(t, 1=6.8 Hz, 2H), 2.53 (t, 1=2.4 Hz, lH), 2.07-2.26 (m, 2H); 
13C NMR (D20/TFA=20/1, 100 MHz) Ii 171.3, 80.0, 72.0,
51.4, 28.8, 26.0, 17 .8; HRESI calculated for C7H12N02S 
([M+Hr) m/z 174.0583; measured m/z 174.0582. 
Example 
(2S)-2-amino-4-(prop-2-yn-1-ylselanyl)butanoic 
acid ( compound 4-Se) 
FIG. 12 with propargyl bromide yielded compound 4-Se 
(0.8 mg, 16% yield) as a white solid. 1H NMR (D20, 400 
MHz) Ii 3.97 (t, 1=6.3 Hz, lH), 3.15 (t, l=l.6 Hz, 2H), 2.74 
10 
(2S)-2-amino-4-[ ( cyanomethyl)selanyl]butanoic acid 
( compound 6-Se) 
FIG. 13 with bromoacetonitrile yielded compound 6-Se 
(1.2 mg, 20% yield) as a white solid. 1H NMR (D20, 400 
MHz) Ii 3.91 (t, 1=6.5 Hz, lH), 3.29 (s, 2H), 2.81 (dd, 
1=15.6, 6.8 Hz, lH), 2.77 (dd, 1=13.2, 6.8 Hz, lH), 2.11-2.29 
(m, 2H); 13C NMR (D20, 100 MHz) Ii 172.3, 119.6, 53.2,
15 30.4, 19.9, 1.9; HRESI calculated for C6H11N202Se ([M+ 
Hr) 222.9980; measured m/z 222.9973. 
Example 
20 (2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic 
acid ( compound 7) 
FIG. 11 with ally! bromide yielded compound 7 (5.3 mg, 
41% yield) as a white solid. 1H NMR (D20/TFA=20/1, 400 
25 
MHz) ll 5.61-5.72 (m, lH), 5.04 (d, 1=10.8 Hz, lH), 4.98 (d, 
1=2.0 Hz, lH), 3.85 (t, 1=6.8 Hz, lH), 3.05 (dd, 1=7.2, 0.8 
Hz, 2H), 2.48 (t, 1=7.6 Hz, 2H), 1.92-2.10 (m, 2H); 13C
NMR (DMSO-d6/TFA-d1=8/1, 125 MHz) Ii 171.2, 134.9, 
117.9, 51.5, 34.0, 30.4, 25.9; HRESI calculated for 
C7H14N02S ([M+Hr) m/z 176.0740; measured m/z 
30 176.0728. 
35 
Example 
(2S)-2-amino-4-(prop-2-en-1-ylselanyl)butanoic 
acid ( compound 7 -Se) 
FIG. 12 with ally! bromide yielded compound 7-Se (3.0 
mg, 59% yield) as a white solid. 1H NMR (D20, 400 MHz) 
Ii 5.70-5.77 (m, lH), 4.9 (m, 2H), 3.90 (t, 1=6.3 Hz, lH), 
40 3.08 (d, 1=7.8 Hz, 2H), 2.45 (t, 1=8.2 Hz, 2H), 2.03-2.10 (m,
2H); 13C NMR (D20, 100 MHz) ll 172.1, 134.6, 116.6, 53.2, 
30.5, 25.2, 16.7; HRESI calculated for C7H14N02Se ([M+ 
Hr) m/z 224.0184; measured m/z 224.0179. (t, 1=7.6 Hz, 2H), 2.49 (t, 1=2.6 Hz, lH), 2.08-2.27 (m, 2H); 
13C NMR (D20, 100 MHz) ll 172.0, 81.3, 72.0, 53.0, 30.3,
18.4, 6.3; HRESI calculated for C7H12N02Se ([M+Hr) m/z 45 
222.0028; measured m/z 222.0035. 
Example 
Example 
(2S)-2-amino-4-(propa-l ,2-dien-1-ylsulfanyl)bu­
tanoic acid ( compound 5) 
FIG. 10 with propargyl bromide yielded compound 5 (0.3 
mg, 6% yield) as a white oil together with compound 4 ( 4.5 
mg, 75% yield) as a white solid. 5.69 (t, 1=6.4 Hz, lH), 4.94 
(d, 1=10.4 Hz, 2H), 4.06 (t, 1=6.4 Hz, lH), 2.70 (t, 1=7.6 Hz, 
2H), 2.07-2.19 (m, 2H); HRESI calculated for C7H12N02S 
([M+Hr) m/z 174.0583; measured m/z 174.0582. 
Example 
(2S )-2-amino-4-[ ( cyanomethyl )sulfanyl ]butanoic 
acid ( compound 6) 
(2S)-2-amino-4-(propylsulfanyl)butanoic acid 
( compound 8) 
50 A protocol identical to that described for compound 3 
using L-homocystine (150 mg, 0.559 mmol) and 1-bro­
mopropane (112 µL, 1.23 mmol) gave compound 8 (181 mg, 
91% yield) as a white amorphous solid. 1H NMR (DMSO­
diTFA-d1=20/1, 400 MHz) Ii 4.05 (t, 1=6.8 Hz, lH), 2.61 
55 (m, 2H), 2.50 (t, 1=7.3 Hz, 2H), 2.03-2.09 (m, 2H), 1.56 
(quin, 1=7.3 Hz, 2H), 0.96 (t, 1=7.2 Hz, 3H); 13C NMR
(DMSO-diTFA-d1=20/1, 125 MHz) Ii 171.2, 51.5, 33.3, 
30.6, 26.9, 22.9, 13.6; HRESI calculated for C7H16N02S 
([M+Hr) m/z 178.0896; measured m/z 178.0900. 
60 
Example 
(2S)-2-amino-4-(propylselanyl)butanoic acid ( com­
pound 8-Se) 
FIG. 11 with L-homocysteine (10 mg, 74 µmo!) and 65 
bromoacetonitrile yielded compound 6 (7.6 mg, 59% yield) FIG. 13 with 1-bromopropane yielded compound 8-Se 
(3.1 mg, 50% yield) as a white solid. 1H NMR (D20, 400 as a white solid. 
1H NMR (D20, 500 MHz) Ii 4.10 (t, 
US 9,879,043 Bl 
33 
MHz) Ii 3.97 (t, 1=6.8 Hz, lH), 2.34 (t, 1=7.6 Hz, 2H), 2.27 
(t, 1=7.0 Hz, 2H), 1.95-2.13 (m, 2H), 1.30 (dt, 1=7.2, 7.0 Hz, 
2H), 0.59 (t, 1=7.2 Hz, 3H); 13C NMR (D20, 100 MHz) Ii 
171.3, 52.6, 30.4, 25.9, 22.9, 17.1, 13.5; HRESI calculated 
for C7H16N02Se ([M+Hi
+) m/z 226.0341; measured m/z 5 
226.0353. 
Example 
34 
Example 
(2S)-2-amino-4-[ (2E)-but-2-en-1-ylsulfanyl]butanoic 
acid ( compound 11) 
(2S)-2-amino-4-(propan-2-ylsulfanyl)butanoic acid 
(compound 9) 
FIG. 10 with 2-bromopropane yielded compound 9 (1.2 
mg, 22% yield) as a white solid. 1H NMR (D20, 400 MHz) 
Ii 4.01 (t, 1=6.5 Hz, lH), 2.89 (quin, 1=6.8 Hz, lH), 2.59 (t, 
1=7.4 Hz, 2H), 1.96-2.12 (m, 2H), 1.09 (d, 1=6.7 Hz, 6H); 
13C NMR (D20, 100 MHz) ll 171.8, 52.0, 34.2, 29.8, 24.8, 
22.2 (2 carbons); HRESI calculated for C7H16N02S ([M+ 
Hr) m/z 178.0896; measured m/z 178.0887. 
A protocol identical to that described for compound 3 
using L-homocystine (150 mg, 0.559 mmol) and (2E)-1-
bromo-2-butene (125 µL, 1.23 mmol) gave compound 11 
(169 mg, 80% yield) as a white amorphous solid. 1 H NMR 
10 (D20, 400 MHz) ll 5.40 (m, lH), 5.24 (m, lH), 3.97 (t, 1=6.0 
Hz, lH), 2.92 (d, 1=7.2 Hz, 2H), 2.42 (t, 1=7.6 Hz, 2H), 
1.91-2.03 (m, 2H), 1.44 (d, 1=5.6 Hz, 3H); 13C NMR (D20, 
100 MHz) Ii 171.4, 129.8, 125.9, 51.7, 32.4, 29.11, 24.6, 
16.7. HRESI calculated for C8H16N02S ([M+Hr) m/z 
15 190.0896; measured m/z 190.0904. 
20 
Example 
Example 
(2S)-2-amino-4-[ (2-methylprop-2-en-1-yl)sulfanyl] 
butanoic acid (compound 12) 
A protocol identical to that described for compound 3 
using L-Homocystine (150 mg, 0.559 mmol) and 3-bromo-
2-methylpropene (223 µL, 2.20 mmol) gave Compound 12 (2S)-2-amino-4-(propan-2-ylselanyl)butanoic acid 
( compound 9-Se) 2
5 (169 mg, 80% yield) was obtained as a white amorphous
solid. 1H NMR (DMSO-diTFA-d1=20/1, 400 MHz) ll 4.88 
(dd, 1=4.6, 3.2 Hz, 2H), 4.04 (t, 1=6.4 Hz, lH), 3.15 (s, 2H), 
2.53 (m, 2H), 2.05-2.09 (m, 2H), 1.78 (s, 3H); 13C NMR 
(DMSO-diTFA-d1=20/1, 125 MHz) ll 171.1, 141.4, 136.5, 
FIG. 14 with 2-bromopropane (0.24 mL, 2.54 mmol) 
yielded compound 9-Se (10 mg, 9% yield) as a white solid. 
L-selenomethionine (94.9 mg) was recovered after flash
reversed-phase chromatography via Method C. 1H NMR
(D20, 400 MHz) ll 3.83 (t, 1=6.3 Hz, lH), 3.09 (quin, 1=6.85 
Hz, lH), 2.55 (t, 1=7.8 Hz, 2H), 2.04-2.17 (m, 2H), 1.24 (d,
1=7.0 Hz, 6H); 13C NMR (D20, 100 MHz) Ii 110.0, 53.9,
31.3, 29.4, 23.5, 23.4, 16.7; HRESI calculated for 35 
C7H16N02Se ([M+Hr) m/z 226.0341; measured m/z 
226.0333. 
Example 
(2S)-2-amino-4-(but-3-yn-1-ylsulfanyl)butanoic acid 
(compound 10) 
FIG. 10 with 4-bromo-1-butyne yielded compound 10 
(1.9 mg, 33% yield) as a white oil. 1H NMR (D20, 400 
MHz) Ii 3.88 (t, 1=6.4 Hz, lH), 2.62 (t, 1=5.2 Hz, 2H), 2.58 
30 51.5, 38.4, 30.1, 26.1, 20.8; HRESI calculated for 
C8H16N02S ([M+Hr) m/z 190.0896; measured m/z 
190.0904. 
Example 
(2S)-2-amino-4-[ (2-methylprop-2-en-1-yl)selanyl] 
butanoic acid (compound 12-Se) 
FIG. 12 with 3-bromo-2-methylpropene yielded com-
40 pound 12-Se (5.0 mg, 85% yield) as a white solid. 1H NMR
(D20, 400 MHz) Ii 4.6 (m, 2H), 3.99 (t, 1=6.5 Hz, lH), 3.11 
(s, 2H), 2.43-2.50 (m, 2H), 1.98-2.11 (m, 2H), 1.54 (s, 3H); 
13C NMR (D20, 100 MHz) ll 171.4, 142.4, 113.0, 52.7, 30.5, 
30.3, 20.0, 17.2; HRESI calculated for C8H15N02SeNa 
45 ([M+Nar) m/z 260.0160; measured m/z 260.0157.
Example 
(t, 1=7.2 Hz, 2H), 2.40 (td, 1=6.8 Hz, 2.4 Hz, lH), 2.27 (t, 
1=2.54 Hz, lH), 1.98-2.14 (m, 2H); 13C NMR (D20, 100 
MHz) Ii 172.8, 83.6, 70.3, 52.7, 29.8, 29.5, 26.4, 18.6; 50 
HRESI calculated for C8H14N02S ([M+Hr) m/z 188.0740; 
measured m/z 188.0759. 
(2S)-2-amino-4-(butylsulfanyl)butanoic acid 
( compound 13) 
FIG. 10 with 1-bromobutane yielded compound 13 (6.4 
mg, 99% yield) as a white solid. 1H NMR (D20, 400 MHz) 
ll 4.00 (t, 1=6.3 Hz, lH), 2.56 (t, 1=7.4 Hz, 2H), 2.45 (t, 1=7.2 Example 
(2S)-2-amino-4-(but-3-yn-1-ylselanyl)butanoic acid 
(compound 10-Se) 
55 Hz, 2H), 1.96-2.11 (m, 2H), 1.41 (quin, 1=7.4 Hz, 2H), 1.23 
(dt, 1=7.4, 6.8 Hz, 2H), 0.73 (t, 1=7.2 Hz, 3H); 13C NMR 
(D20, 100 MHz) ll 172.0, 52.1, 30.6, 30.4, 29.5, 26.2, 21.2, 
12.7; HRESI calculated for C8H18N02S ([M+Hr) m/z 
192.1053; measured m/z 192.1074. 
FIG. 13 with 4-bromo-1-butyne yielded compound 10-Se 60 
(2.1 mg, 33% yield) as a light yellow solid. 1H NMR (D20, 
400 MHz) Ii 3.92 (t, 1=6.3 Hz, lH), 2.61 (t, 1=6.8 Hz, 2H), 
2.57 (t, 1=8.0 Hz, 2H), 2.44 (td, 1=7.2 Hz, 2.8 Hz, 2H), 2.20 
(t, 1=2.4 Hz, lH), 2.02-2.20 (m, 2H); 13C NMR (D20, 100 
MHz) Ii 172.1, 84.3, 70.1, 53.1, 30.7, 21.4, 19.5, 17.7; 65 
HRESI calculated for C8H14N02Se ([M+Hr) m/z 
236.0184; measured m/z 236.0200. 
Example 
(2S )-2-amino-4-(buty lselany 1) butanoic acid ( com­
pound 13-Se) 
FIG. 13 with 1-bromobutane yielded compound 13-Se 
(9.3 mg, 100% yield) as a white solid. 1H NMR (D20, 400 
US 9,879,043 Bl 
35 
MHz) ll 4.01 (t, 1=6.5 Hz, lH), 2.53 (m, 4H), 2.05-2.15 (m, 
2H), 1.49 (quin, 1=7.4 Hz, 2H), 1.23 (dt, 1=7.6, 7.4 Hz, 2H), 
0.74 (t, 1=7.4 Hz, 3H); 13C NMR (D20, 100 MHz) ll 171.8, 
52.8, 31.6, 30.6, 23.4, 22.2, 17.1, 12.6; HRESI calculated for 
C8H18N02Se ([M+Hr) m/z 240.0497; measured m/z 5 
240.0510. 
Example 
(2S )-2-amino-4-[ (2-methylpropy 1 )sulfany l ]butanoic 
acid (compound 14) 
10 
FIG. 10 with 2-bromo-propane yielded compound 14 (6.4 
mg, 99% yield) as a white solid. 1H NMR (D20/TFA=20/1, 
400 MHz) Ii 4.04 (t, 1=6.3 Hz, lH), 2.54 (t, 1=7.4 Hz, 2H), 15 
2.32 (d, 1=7.0 Hz, 2H), 2.00-2.12 (m, 2H), 1.6 (m, lH), 0.78 
36 
1=16.8, 1.6 Hz, lH), 4.80 (dd, 1=10.8, 1.4 Hz, lH), 3.91 (t, 
1=6.5 Hz, lH), 2.95 (d, 1=7.4 Hz, 2H), 2.35 (t, 1=7.2 Hz, 
2H), 1.80-1.99 (m, 2H); 13C NMR (D20, 100 MHz) ll 171.2, 
136.1, 133.5, 129.2, 117.2, 51.3, 32.1, 29.0, 24.8. HRESI 
calculated for C9H16N02S ([M+Hr) m/z 202.0896; mea­
sured m/z 202.0905. 
Example 
(2S)-2-amino-4-[(2-azidoethyl)sulfanyl]butanoic 
acid ( compound 17) 
FIG. 9 with dibromomoethane (0.46 mL, 5.32 mmol) 
yielded a mixture of dibromoethane: l-azido-2-bromoethane 
(1:2, 1.0 g). FIG. 10 with this mixture yielded compound 17 
(2.1 mg, 33% yield) as a white solid together with dimer 
Compound 28 (4.2 mg, 46% yield) as a white solid. Com­
pound 17: 1H NMR (D20, 400 MHz) ll 3.88 (t, 1=6.5 Hz, 
lH), 3.39 (t, 1=6.5 Hz, 2H), 2.65 (t, 1=6.5 Hz, 2H), 2.58 (t, 
(d, 1=6.7 Hz, 6H); 13C NMR (D20/TFA=20/1, 100 MHz) Ii 
171.5, 51.6, 39.9, 29.4, 27.7, 26.8, 21.0 (2 carbons); HRESI 
calculated for C8H18N02S ([M+Hr) m/z 192.1053; mea­
sured m/z 192.1043. 
Example 
20 1=7.4 Hz, 2H), 1.96-2.11 (m, 2H); 13C NMR (D20, 100 
MHz) Ii 172.6, 52.5, 50.2, 30.2, 29.8, 26.5; HRESI calcu­
lated for C6H13N402S ([M+Ht) m/z 205.0754; measured 
m/z 205.0767. 
(2S)-2-amino-4-[(3-aminopropyl)sulfanyl]butanoic 
acid ( compound 15) 25 
FIG. 10 with 3-bromopropylamine hydrobromide yielded 
compound 15 (1.4 mg, 24% yield) as a white solid. 1 H NMR 
(D20, 400 MHz) ll 3.89 (t, 1=6.3 Hz, lH), 2.96 (t, 1=7.6 Hz, 
2H), 2.51-2.58 (m, 4H), 1.99-2.10 (m, 2H), 1.82 (quin, 1=7.3 30 
Hz, 2H); 13C NMR (D20, 100 MHz) Ii 172.8, 52.6, 38.3, 
29.7, 27.3, 26.2 (2 carbons); HRESI calculated for 
C7H17N202S ([M+Hr) m/z 193.1005; measured m/z 
193.1019. 
Example 
(2S)-2-amino-4-[(3-methylbutyl)sulfanyl]butanoic 
acid ( compound 18) 
FIG. 10 with l-bromo-3-methylbutane yielded compound 
18 (6.5 mg, 99% yield) as a white solid. 1H NMR (D20/ 
TFA=20/1, 400 MHz) ll 4.03 (t, 1=6.5 Hz, lH), 2.52 (t, 1=7.4 
Hz, 2H), 2.41 (t, 1=7.8 Hz, 2H), 1.94-2.05 (m, 2H), 1.38-
1.47 (m, lH), 1.23-1.31 (q, 1=7.6 Hz, 2H), 0.68 (d, 1=6.7 Hz, 
Example 
(2S)-2-amino-4-[(3-aminopropyl)selanyl]butanoic 
acid (compound 15-Se) 
35 6H); 13C NMR (D20/TFA=20/1, 100 MHz) Ii 171.5, 51.6, 
37.5, 29.3, 28.7, 26.6, 26.1, 21.3 (2 carbons). HRESI cal­
culated for C9H20N02S ([M+Ht) m/z 206.1209; measured 
m/z 206.1223. 
40 
FIG. 13 with 3-bromopropylamine hydrobromide yielded 
compound 15-Se (5.7 mg, 86% yield) as a white solid. 1H 
NMR (D20, 400 MHz) Ii 3.97 (t, 1=6.3 Hz, lH), 2.94 (t, 
1=7.4 Hz, 2H), 2.56 (m, 4H), 2.08-2.13 (m, 2H), 1.87 (quin, 
1=7.4 Hz, 2H); 13C NMR (D20, 100 MHz) Ii 172.0, 52.9, 45 
39.1, 30.6, 27.2, 19.1, 17.5. HRESI calculated for 
C7H17N202Se ([M+Ht) m/z 241.0450; measured m/z 
241.0465. 
Example 
(2S)-2-amino-4-[ (3-methylbut-2-en-1-yl)sulfanyl] 
butanoic acid (compound 19) 
A protocol identical to that described for compound 3 
using L-Homocystine (150 mg, 0.559 mmol) and 3,3-dim­
ethylallyl bromide (250 µL, 2.15 mmol) gave compound 19 
(304 mg, 76% yield) as a white amorphous solid. 1H NMR 
(DMSO-diTFA-d1=20/1, 500 MHz) Ii 5.16 (t, 1=7.8 Hz, 
Example 
(2S)-2-amino-4-[ (2E)-penta-2,4-dien-1-ylsulfanyl] 
butanoic acid (compound 16) 
50 lH), 4.00 (t, 1=6.2 Hz, lH), 3.12 (d, 1=7.7 Hz, 2H), 
2.49-2.56 (m, 2H), 1.94-2.04 (m, 2H), 1.68 (s, 3H), 1.61 (s, 
3H); 13C NMR (DMSO-d6/TFA-d1=20/1, 125 MHz) Ii 
175.8, 140.1, 125.7, 56.3, 35.5, 33.8, 31.3, 30.7, 22.9; 
HRESI calculated for C9H18N02S ([M+Hr) m/z 204.1053; 
According to the protocol reported by Sato et al., [28] to 55 measured m/z 204.1053. 
a 50 mL solution of 1,4-pentadien-3-ol (0.5 g, 5.94 mmol) 
in water was added 48% HBr in water (1.2 g, 7.13 mmol) 
drop wise. The reaction was stirred at 0° C. until TLC 
indicated the reaction was complete (-2 h). The reaction was 
then diluted with ether and washed with NaHC03 (sat, 3x30 60 
mL), water, and brine. The organic layer was dried with 
Na2S04 and concentrated in vacuo to afford 4-bromo-1,3-
pentadiene (0.46 g, 3.2 mmol) as a yellow liquid with a yield 
of 53%. FIG. 10 with this 4-bromo-1,3-pentadiene yielded 
compound 16 (1.4 mg, 22%) as a white solid. 1H NMR 65 
(D20, 400 MHz) Ii 6.10 (dt, 1=17.1, 10.2 Hz, lH), 5.92 (dd, 
1=15.3, 10.6 Hz, lH), 5.42 (dt, 1=15.1, 7.7 Hz, lH), 4.94 (dd, 
Example 
(2S)-2-amino-4-[ (3-methylbut-2-en-1-yl)selanyl] 
butanoic acid (compound 19-Se) 
FIG. 13 with 3,3-dimethylallyl bromide yielded com­
pound 19-Se (2.8 mg, 41 % yield) as a white solid. 1H NMR 
(D20/TFA=20/1, 400 MHz) Ii 5.19-5.26 (m, lH), 3.92 (t, 
1=6.3 Hz, lH), 3.17 ( d, 1=8.6 Hz, 2H), 2.49 (t, 1=8.0 Hz, 
2H), 2.04-2.18 (m, 2H), 1.59 (s, 3H), 1.52 (s, 3H); 13C NMR 
(D20/TFA=20/1, 100 MHz) Ii 175.8, 140.1, 125.7, 56.4, 
US 9,879,043 Bl 
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35.5, 33.8, 31.3, 30.7, 22.9. HRESI calculated for 
C9H18N02Se ([M+Hr) m/z 252.0497; measured m/z 
252.0512. 
Example 
(2S)-2-amino-4-( cyclohex-2-en-1-ylsulfanyl)bu­
tanoic acid ( compound 20) 
38 
138.0, 128.8 (2 carbons), 128.7 (2 carbons), 127 .2, 51.4, 
34.6, 29.1, 25.5; HRESI calculated for CuH15N02SNa 
([M+Nar) m/z 248.0716; measured m/z 248.0716. 
Example 
(2S)-2-amino-4-(benzylselanyl)butanoic acid ( com­
pound 22-Se) 
FIG. 11 with 3-bromo-cyclohexene yielded compound 20 
(4.6 mg, 30% yield) as a white solid. 1H NMR (D20, 400 
MHz) Ii 5.70-5.77 (m, lH), 5.56 (d, 1=8.2 Hz, lH), 4.01 (dt, 
1=6.4, 0.3 Hz, lH), 3.37 (br. s, lH), 2.54-2.69 (m, 2H), 
1.97-2.20 (m, 2H), 1.77-1.89 (m, 3H), 1.39-1.66 (m, 3H); 
13C NMR (D20, 100 MHz) Ii 171.8, 131.1, 126.7, 51.9, 
39.94, 39.91, 28.54, 28.51, 24.2, 19.0; HRESI calculated for 
C10H18N02S ([M+Hr) m/z 216.1053; measured m/z 
216.1043. 
1° FIG. 11 with L-selenomethionine (100 mg, 0.51 mmol) 
and benzyl bromide (0.24 mL, 2.03 mmol) yielded com­
pound 22-Se (10 mg, 7% yield) as a white solid 
and L-selenohomocystine (70 mg, 0.19 mmol, 38% yield). 
1H NMR (D20, 400 MHz) Ii 7.11 (s, 2H), 7.10 (s, 2H), 
15 7.00-7.06 (m, lH), 3.86 (t, 1=6.5 Hz, lH), 3.62 (s, 2H),
2.33-2.39 (m, 2H), 1.90-1.97 (m, 2H); 13C NMR (D20, 100 
MHz) ll 171.2, 139.2, 129.0 (2 carbons), 128.6 (2 carbons), 
126.8, 46.4, 42.9, 30.3, 26.2; HRESI calculated for 
Cu H16N02Se ([M+Ht) m/z 274.0341; measured m/z 
Example 20 274.0339. 
(2S)-2-amino-4-( cyclohex-2-en-1-ylselanyl)butanoic 
acid ( compound 20-Se) 
FIG. 13 with 3-bromo-cyclohexene yielded compound 25 
20-Se (1.3 mg, 18% yield) as a white solid. 1H NMR (D20,
400 MHz) Ii 5.64-5.72 (m, 2H), 3.90 (m, lH), 3.58-3.66 (m, 
lH), 2.86 (t, l=l.00 Hz, lH), 2.52-2.68 (m, 2H), 2.05-2.20 
(m, 2H), 1.90 (br. s, 2H), 1.50-1.70 (m, 3H); 13C NMR 
(D20, 100 MHz) Ii 172.3, 131.4, 127.7, 53.4, 36.2, 31.5, 30 
29.5, 24.2, 19.2, 17.6; HRESI calculated for C10H18N02S 
([M+Hr) m/z 264.0497; measured m/z 264.0508. 
Example 
Example 
(2S)-2-amino-4-{ [ (2E)-4-azidobut-2-en-1-yl] 
sulfanyl}butanoic acid (compound 23) 
FIG. 9 with (E)-1,4-dibromobut-2-ene (2.0 g, 9.34 mmol) 
yielded a mixture of (E)-1-azido-4-bromobut-2-ene:(E)-1,4-
dibromobut-2-ene (3:2, 2.31 g). FIG. 10 with this (E)-1-
azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture 
yielded 23 (1.3 mg, 18% yield) as a white solid together with 
dimer compound 30 (2.3 mg, 23% yield) as a white solid. 
Compound 23: 1H NMR (D20, 400 MHz) Ii 5.52-5.69 (m, 
2H), 3.94 (t, 1=6.5 Hz, lH), 3.66 (d, 1=6.3 Hz, 2H), 3.09 (d, 
(2S)-2-amino-4-[(3-azidopropyl)sulfanyl]butanoic 
acid ( compound 21) 
35 1=6.7 Hz, 2H), 2.49 (t, 1=7.4 Hz, 2H), 1.92-2.12 (m, 2H); 
13C NMR (D20, 100 MHz) Ii 172.2, 130.9, 126.4, 52.1, 
51.6, 31.7, 29.3, 24.9; HRESI calculated for C8H15N402S 
([M+Hr) m/z 231.0910; measured m/z 231.0922. 
FIG. 9 with dibromopropane (0.50 mL, 4.98 mmol) 
yielded a mixture of dibromopropane:1-azido-3-bromopro- 40 
pane (2:5, 1.0 g). FIG. 10 with this mixture yielded com­
pound 21 (1.7 mg, 25% yield) as a white solid together with 
dimer compound 29 (1.0 mg, 10% yield) as a white solid. 
Compound 21: 1H NMR (D20, 400 MHz) Ii 3.93 (t, 1=6.5 
Hz, lH), 3.26 (t, 1=6.7 Hz, 2H), 2.54 (t, 1=7.6 Hz, 2H), 2.49 45 
(t, 1=7.2 Hz, 2H), 1.93-2.14 (m, 2H), 1.70 (quin, 1=6.8 Hz, 
2H); 13C NMR (D20, 100 MHz) ll 172.3, 52.3, 49.7, 29.5, 
27.69, 27.65, 26.3. HRESI calculated for C7H15N402S 
([M+Hr) m/z 219.0910; measured m/z 219.0919. 
Example 
(2S)-2-amino-4-{ [ (2E)-4-azidobut-2-en-1-yl] 
selanyl}butanoic acid (compound 23-Se) 
FIG. 12 with the (E)-1-azido-4-bromobut-2-ene:(E)-1,4-
dibromobut-2-ene mixture in the synthesis of compound 23 
yielded compound 23-Se (3.1 mg, 36% yield) as a white 
solid. 1H NMR (D20, 400 MHz) Ii 5.77-5.88 (m, lH), 
5.42-5.51 (m, lH), 3.89 (t, 1=6.l Hz, lH), 3.44 (d, 1=6.7 Hz, 
Example 
(2S)-2-amino-4-(benzylsulfanyl)butanoic acid 
(compound 22) 
50 2H), 3.12 (d, 1=7.4 Hz, 2H), 2.41-2.50 (m, 2H), 2.07-2.10 
(m, 2H); 13C NMR (D20, 100 MHz) ll 169.8, 134.2, 122.7, 
53.2, 40.3, 30.5, 23.3, 16.8; HRESI calculated for 
C8H15N402Se ([M+Hr) m/z 279.0355; measured m/z 
279.0348. 
55 
A protocol similar to that described for compound 3 using 
L-Homocystine (250 mg, 0.93 mmol) and benzyl bromide
(0.13 mL, 1.12 mmol) was employed with slight modifica­
tions. Specifically, after the evaporation of NH3 the dried
residue was dissolved in 15 mL ddH20 and the pH subse- 60 
quently adjusted to 7 by adding 1 M HCI. A heavy precipi­
tate formed, which was filtered and washed with cold ddH20
(3x10 mL). The filtrate was purified by recrystallization
from ethanol to provide compound 22 (0.15 g, 72% yield).
1H NMR (D20/TFA=20/1, 400 MHz) Ii 7.08-7.19 (m, SH), 65 
3.92 (t, 1=6.3 Hz, lH), 3.57 (s, 2H), 2.37 (t, 1=8.2 Hz, 2H),
1.84-2.04 (m, 2H); 13C NMR (D20, 100 MHz) Ii 171.3,
Example 
(2S)-2-amino-4-{ [ (2E)-4-aminobut-2-en-1-yl] 
selanyl} butanoic acid ( compound 24-Se) 
(E)-1-azido-4-bromobut-2-ene was synthesized according 
to the procedure reported by Islam et al.[29] (E)-1,4-dibro­
mobut-2-ene (2 g, 9.34 mmol) was placed in a round-bottom 
flask and dissolved in THF (10 mL). Sodium azide (800 mg, 
12.2 mmol) was dissolved in 1 mL water and mixed the 
solution of (E)-1,4-dibromobut-2-ene. The reaction was 
stirred overnight at room temperature, diluted with diethyl 
US 9,879,043 Bl 
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400 MHz) Ii 8.05 (d, 1=9.0 Hz, 2H), 7.41 (d, 1=9.0 Hz, 2H), 
3.88 (t, 1=6.4 Hz, lH), 3.83 (s, 2H), 2.47 (t, 1=6.8 Hz, 2H), 
1.96-2.03 (m, 2H); 13C NMR (D20, 100 MHz) Ii 171.9, 
147.9, 146.2, 129.5 (2 carbons), 123.9 (2 carbons), 52.9, 
30.5, 25.4, 17.7; HRESI calculated for C11H15N204SE 
([M+Hr) m/z 319.0192; measured m/z 319.0201. 
Example 
(2S)-2-amino-4-[(2-{[(3S)-3-amino-3-carboxypro­
pyl]sulfanyl }ethyl)sulfanyl]butanoic acid ( com­
pound 28) 
ether (100 mL) and successively washed with water (15 mL) 
and saturated NaCl solution (15 mL). The organic layer was 
dried over anhydrous Na2S04 and evaporated under reduced 
pressure. Crude products were purified by flash silica gel 
column chromatography using EtOAc/Hexanes affording 5 
200 mg of (E)-1-azido-4-bromobut-2-ene (25% yield) and 
320 mg of (E)-1,4-diazidobut-2-ene (25% yield), both as 
colorless liquids. FIG. 13 with (E)-1-azido-4-bromobut-2-
ene yielded compound 24-Se (2.6 mg, 45% yield) as a white 
solid. 1H NMR (D20, 400 MHz) Ii 5.71-6.05 (m, lH), 10 
5.37-5.59 (m, lH), 3.75 (t, 1=6.l Hz, lH), 3.45 (d, 1=6.7 Hz, 
2H), 3.12 (d, 1=7.4 Hz, 2H), 2.37-2.45 (m, 2H), 2.01-2.07 
(m, 2H); 13C NMR (D20, 100 MHz) ll 173.2, 134.1, 122.8, 
54.0, 40.4, 30.9, 23.3, 16.7; HRESI calculated for 
C3H17N202Se ([M+Ht) m/z 253.0450; measured m/z 
253.0464. 15 
FIG. 9 with dibromoethane (0.46 mL, 5.32 mmol) yielded 
a mixture of dibromoethane: l-azido-2-bromoethane (1:2, 
1.0 g). FIG. 10 with this dibromoethane:1-azido-2-bro­
moethane mixture yielded compound 17 (2.1 mg, 33%) as a 
white solid together with dimer compound 28 ( 4.2 mg, 46%) 
Example 
(2S)-2-amino-4-{ [ ( 4-methylphenyl)methyl] 
sulfanyl}butanoic acid (compound 25) 
FIG. 10 with 4-methylbenzyl bromide yielded compound 
25 (2.0 mg, 27% yield) as a white solid. 1 H NMR (D20, 400 
MHz) ll 7.05 (d, 1=8.0 Hz, 2H), 7.00 (d, 1=8.0 Hz, 2H), 3.93 
(t, 1=6.3 Hz, lH), 3.53 (s, 2H), 2.36 (t, 1=7.4 Hz, 2H), 2.07 
(s, 3H), 1.90-2.09 (m, 2H); 13C NMR (D20, 100 MHz) Ii 
171.3, 137.4, 134.9, 129.2 (2 carbons), 128.8 (2 carbons), 
51.5, 34.3, 29.1, 25.6, 19.9; HRESI calculated for 
C12H18N02S ([M+Hr) m/z 240.1053; measured m/z 
240.1061. 
Example 
(2S)-2-amino-4-{ [ (2E)-3-phenylprop-2-en-1-yl] 
sulfanyl}butanoic acid (compound 26) 
FIG. 10 with 3-bromo-l-phenyl-1-propene yielded com­
pound 26 (4.2 mg, 54% yield) as a white solid. 1H NMR
(D20, 400 MHz) ll 7.23 (d, 1=7.0 Hz, 2H), 7.13 (t, 1=7.4 Hz, 
2H), 7.05 (dd, 1=14.5, 7.4 Hz, lH), 6.32 (d, 1=16.0 Hz, lH), 
6.03 (dt, 1=16.0, 7.4 Hz, lH), 3.96 (t, 1=6.5 Hz, lH), 3.14 (d, 
1=7.4 Hz, 2H), 2.44 (t, 1=7.4 Hz, 2H), 1.93-2.05 (m, 2H); 
13C NMR (D20, 100 MHz) Ii 171.3, 136.4 (2 carbons), 
132.1, 128.7 (2 carbons), 126.2, 125.5, 110.0, 51.6, 32.8, 
29.2, 24.9; HRESI calculated for C13H18N02S ([M+Hr) 
m/z 252.1053; measured m/z 252.1075. 
Example 
(2S)-2-amino-4-{ [ ( 4-nitrophenyl)methyl] 
sulfanyl}butanoic acid (compound 27) 
FIG. 11 with 4-nitrobenzyl bromide yielded compound 27 
(3.6 mg, 18% yield) as a white solid. 1H NMR (D20, 400 
MHz) Ii 8.06 (d, 1=9.0 Hz, 2H), 7.43 (d, 1=9.0 Hz, 2H), 3.94 
20 as a white solid. Compound 28: 
1 H NMR (D20, 400 MHz) 
ll 3.95 (t, 1=6.3 Hz, 2H), 2.68 (s, 4H), 2.58 (t, 1=7.4 Hz, 4H), 
1.94-2.15 (m, 4H); 13C NMR (D20, 100 MHz) Ii 172.2 (2 
carbons), 52.1 (2 carbons), 30.4 (2 carbons), 29.6 (2 car­
bons), 26.3 (2 carbons); HRESI calculated for 
25 C10H21N204S2 ([M+Ht) m/z 297.0937; measured m/z 
297.0949. 
30 
Example 
(2S)-2-amino-4-[(3-{[(3S)-3-amino-3-carboxypro­
py l] sulfany 1} propyl )sulfanyl ]butanoic acid ( com­
pound 29) 
FIG. 9 with dibromopropane (0.50 mL, 4.98 mmol) 
35 yielded a mixture of dibromopropane:1-azido-3-bromopro­
pane (2:5, 1.0 g). FIG. 10 with this dibromopropane: l-azido-
3-bromopropane mixture yielded compound 21 (1.7 mg,
25% yield) as a white solid together with dimer compound
29 (1.0 mg, 10% yield) as a white solid. Compound 29: 1H
40 
NMR (D20, 400 MHz) Ii 3.96 (t, 1=6.3 Hz, 2H), 2.56 (d,
1=7.6 Hz, 4H), 2.50 (d, 1=7.2 Hz, 4H), 1.96-2.12 (m, 4H),
1.71 (quin, 1=7.1 Hz, 2H); 13C NMR (D20, 100 MHz) Ii
172.1 (2 carbons), 52.0 (2 carbons), 29.5 (2 carbons), 29.3
45 (2 carbons), 27.9, 26.2 (2 carbons). HRESI calculated for 
C11H23N204S2 ([M+Ht) m/z 311.1094; measured m/z 
311.1101. 
50 
Example 
(2S)-2-amino-4-{[(2E)-4-{[(3S)-3-amino-3-carboxy­
propyl]sulfanyl} but-2-en-1-yl] sulfanyl} butanoic 
acid (Compound 30) 
(t, 1=6.5 Hz, lH), 3.75 (s, 2H), 2.45 (t, 1=7.0 Hz, 2H), 55 
1.90-2.09 (m, 2H); 13C NMR (D20, 100 MHz) Ii 171.7, 
146.6, 129.7 (2 carbons), 123.8 (2 carbons), 117.6, 51.7, 
34.2, 29.2, 25.8; HRESI calculated for C11H15N204S ([M+ 
Hr) m/z 271.0747; measured m/z 271.0761. 
FIG. 9 with (E)-1,4-dibromobut-2-ene (2.0 g, 9.34 mmol) 
yielded a mixture of (E)-1-azido-4-bromobut-2-ene:(E)-1,4-
dibromobut-2-ene (3:2, 2.31 g). FIG. 10 with this (E)-1-
azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture 
yielded 23 (1.3 mg, 18% yield) as a white solid together with 
Example 
(2S)-2-amino-4-{ [ ( 4-nitrophenyl)methyl] 
selanyl}butanoic acid (compound 27-Se) 
FIG. 13 with 4-nitrobenzyl bromide yielded compound 
27-Se (1.6 mg, 18% yield) as a white solid. 1H NMR (D20,
60 dimer compound 30 (2.3 mg, 23% yield) as a white solid. 
Compound 30: 1 H NMR (D20, 400 MHz) Ii 5.42-5.49 (m, 
2H), 3.98 (t, 1=6.5 Hz, 2H), 3.02-3.10 (m, 4H), 2.48 (t, 1=7.4
Hz, 4H), 1.92-2.15 (m, 4H); 13C NMR (D20, 100 MHz) Ii 
171.9 (2 carbons), 128.9 (2 carbons), 51.9 (2 carbons), 31.8 
65 (2 carbons), 29.2 (2 carbons), 25.0 (2 carbons); HRESI 
calculated for C12H23N204S2 ([M+Ht) m/z 323.1094; mea­
sured m/z 323.1102. 
US 9,879,043 Bl 
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Gene cloning and protein expression and purification. The 
Escherichia Coli MAT ( eMAT) was amplified using colony 
PCR from the cells of E. Coli BL21(DE3) strain using 
primers 
42 
gradient of imidazole of 10-500 mM) using an AKTA 
Purifier 10 (GE Healthcare). Buffer exchange of pooled 
fractions containing the purified protein was accomplished 
using a PD-10 colunm (GE Healthcare) eluted with 25 mM 
5' -ATACTGCATATGGCAAAACACCTTTTTACG 
(forward, NdeI), per SEQ ID NO: 2, and 
5 Tris-HCI, 80 mM KC!, pH 8. Protein concentrations were 
determined by Bradford assay (Bio-Rad, Hercules, Calif., 
USA) using BSA as a standard. For this study, all proteins 
retained the N-terminal-His6 affinity tag. 
10 
5' -CAGTATGGATCCTTACTTCAGACCGGCAGC 
MAT Assay 
In vitro MAT reactions were conducted in a volume of 50 
µI with 2 mM S/Se-alkylated analog (compounds 2-30), 1 
mM ATP and 5 µM purified MAT in 25 mM Tris buffer pH 
8.0, 5 mM MgCl2, 50 mM KC! for 4 h. The sMAT and 
(reverse, BamHI), per SEQ ID NO: 3. The PCR products 
were digested with respective restriction enzymes and 
ligated into pET28a vector to provide expression plasmids 
for proteins bearing N-terminal-His6 fusions. The expression 
constructs for Homo Sapiens MATs (hMATs) were provided 
15 
mMAT reactions were conducted at 65° C. while hMATs and 
by Prof. Chunming Liu. The Methanocaldococcus janna­
schii MAT (mMAT) gene was synthesized (sequence pro­
vided in SEQ ID NO: 1) by GenScript (Piscataway, N.J.) 20 
with N-terminal NdeI and C-terminal EcoRI restriction sites 
and subsequently also subcloned in the pE T28a vector to 
provide an expression construct for the N-terminal-His6 
fusion. Expression and purification of rebeccamycin meth­
yltransferase, RebM was carried out as described in Zhang 25 
et al.5a The E. coli S-adenosylhomocysteine nucleosidase
(EC 3.2.2.9) (also known as SAH hydrolase) gene was 
amplified from the genome of E. coli BL21(DE3), using 
primers 
eMAT were incubated at 3 7° C. Reactions were quenched by 
adding an equal volume of methanol followed by centrifu­
gation (10,000xg for 15 min) to remove the precipitated 
protein and product formation for each reaction was subse­
quently analyzed by RP-HPLC using Method D (FIG. 15, 
first column). For each reaction, percent yield was based 
upon the integration of species at 254 nm and calculated by 
dividing the integrated area of product and/or decomposed 
product by the sum of integrated area of product and/or 
decomposed product and the remaining substrate. The 
assays were repeated twice under identical conditions, and 
Table 2 (and FIG. 5) represents an average value of two 
assays. The inclusion of adenine and 5'-R-thio-5'-adenosine 
in these calculations is based upon the established SAM and 
5' -AGCCATATGA AAATCGGCATCATTGGTG 
(forward, NdeI), per SEQ ID NO: 4, and 
30 ATP chemical decomposition pathways which indicate
adenine and 5'-R-thio-5'-adenosine to only derive from 
SAM (not ATP). All putative products were subsequently 
confirmed by high resolution electrospray ionization (ESI) 
35 
mass spectra with positive ( +) and/or negative (-) mode. 
5' -ATAGAATTCTTAGCCATGTGCAAGTTTCTG 
(reverse, EcoRI), per SEQ ID NO: 5. The PCR products 
were digested with respective restriction enzymes and 
ligated into pET28a vector to provide expression plasmids 
40 
for the corresponding N-terminal-His6 fusion protein. 
All five MATs with N-terminal-His6 (herein referred to 
simply as hMATlA, hMAT2A, hMAT2, eMAT, and 
mMAT), RebM and SAH hydrolase were expressed in a 
corresponding E.coli BL21(DE3) host in the presence of 35 
45 
µg mL-1 of kanamycin at 37° C. to an OD600 of -0.6,
induced with 0.5 mM IPTG, and continued to grow at 37° C. 
for another 4 h. The cells were harvested by centrifugation 
(30 min, 5000 rpm), resuspended in buffer A (20 mM 
NaH2P04, 300 mM NaCl, 10 mM imidazole, pH 7.8). The 50 
cells were lysed via incubation with 1 mg mL-1 lysozyme
(-50,000 U mg-1; Sigma-Aldrich, St. Louis, Mo., USA) for
30 min on ice followed by sonication (VirSonic 475; Virtis, 
Gardiner, N.Y.; 100 W, 4x30 s pulses, -1 min between 
pulses) on ice. MATs were purified via affinity chromatog-
55 
raphy (5 mL Hi Trap Ni-N TA chelating colunm, GE Health­
care, Piscataway, N.J.) following standard linear gradient 
(50 mM NaH2P04, 300 mM NaCl, pH 8.0 with a linear 
Example 
FIG. 18 illustrates the synthesis of (seleno)methionine 
analogs, use of a high-throughput MAT assay, and product 
verification via LC/MS. 
Coupled hMAT2/RebM Assay 
In vitro hMAT2-RebM coupled reactions were carried out 
in a volume of 25 µI with 2 mM S/Se-alkylated analogs, 1 
mM ATP, 50 µM rebeccamycin ortholog compound 31 
(synthesized as previously described), [30] 5 µM hMAT2, 10 
µM RebM, 5 µM SAH hydrolase in 25 mM Tris buffer pH 
8.0, 5 mM MgCl2, 50 mM KC! for 24 h at 37
° C. Reactions 
were quenched by adding an equal volume of methanol 
followed by centrifugation (10,000 g for 15 min) to remove 
the precipitated protein and the product formation for each 
reaction was subsequently analyzed by RP-HPLC using 
Method E (FIG. 15, middle column). The assays were 
repeated twice under identical conditions and Table 2 (and 
FIG. 8) represents an average value of two assays. The 
reactions were scaled (>500 µM compound 31 ), purified by 
semi-prep HPLC using Method E and the putative new 
products were confirmed by NMR ( Table 3) and HRMS. 
TABLE 3 
NMR Chemical Shifts (in PPM) of 4'0-R-Rebeccamycin in CD30D; where R � 
Atom -H -----CH3 -----CH2CH3 -----CH2CHCH2 -----CH2CCH -----CH2CCN 
Cl'/Hl' 86.2/6.20 86.2/6.20 86.2/6.20 86.2/6.20 86.2/6.20 86.2/6.20 
C2'/H2' 74.5/3.83 74.6/3.83 74.4/3.82 74.8/3.81 74.9/3.82 74.8/3.82 
C3'/H3' 78.3/3.74 78.2/3.83 78.2/3.82 78.3/3.87 78.6/3.89 78.3/3.95 
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TABLE 3-continued 
NMR Chemical Shifts (in PPM) of 4'0-R-Rebeccamycin in CD30D; where R � 
Atom -H 
C4'/H4' 69.0/4.26 78.8.0/3.98 77.0/4.07 77.0/4.14 76.8/4.21 78.0/4.26 
C5'/H5' 
C6'/H6', 
80.3/3.99 79.2/3.99 79.2/3.99 79.2/4.05 79.2/4.05 78.73/4.12 
59.8/4.25, 59.9/4.13, 59.9/4.13, 60.0/4.15, 60.2/4.24, 60.1/4.17, 
H6" 4.03 4.03 4.03 4.05 4.04 4.06 
4-0'-H3 
4-0'---CH2CH3 
NA 61.1/3.79[a] NA NA NA NA 
NA NA (69.5/4.09, NA NA NA 
3.96) 
(15.9/1.33) 
4-0'---CH2CHCH2 NA NA NA (74.9/4.59, NA NA 
4.44) (6.10) 
(5.39, 
5.22) [a].[b] 
4-0'---CH2CCH NA NA NA NA (61.0/4.70, NA 
4.63) (2.92jlc] 
4-0'---CH2CCN NA NA NA NA NA (58.3/4.85)[a] 
[alresonances listed as Cl"/Hl", C2"/H2", C3"/H3" in sequential order; 
[b]Bc C2"(CH) and C3" (CH2) were not observed in tbe HSQC; 
[c]Bc C3" (CH) was not observed in the HSQC. 
Example II 
The MAT from Sulfolobus solfataricus (sMAT), an 25
enzyme from a poorly explored class of the MAT family, has 
the ability to produce a range of differentially alkylated 
SAM analogs in the presence of non-native methionine 
analogs and ATP. To investigate the molecular basis for 
SAM analog production, the sMAT in the SAM bound, 30 
S-adenosylethionine (SAE) bound, and unbound forms was
crystallized. Notably, among these structures, the SAE­
bound form offers the first MAT structure containing a
non-native product and cumulatively, these structures add
new structural insight into the MAT family and allow for 35 
detailed active site comparison with its homologs in E. coli 
and humans. As the only existing thermostable MAT struc­
tures from archaea, the structures herein also provide as a
basis for future engineering to broaden SAM analog pro­
duction as reagents for methyltransferase-catalyzed 'alkyl- 40 
randomization' and/or the study of methylation in the con­
text of biological processes.
Some members of the MAT family accommodate non­
native methionine analogs [9, 55] and, in the context of 
coupled reactions containing permissive methyltransferases, 45 
enable the ability for natural product 'alkylrandomization'. 
A sequence divergent class ofMATs has been identified in 
archaea [37, 47], with only -20% sequence identity with E.
coli and human MATs. However, structural information and 
broad substrate specificity assessment for members of this 50 
divergent class of MATs is lacking. The present disclosure 
provides Sulfolobus solfataricus MAT (sMAT) to enable the 
cumulative synthesis of a broad panel of unnatural SAM 
analogs (31 analogs detected) starting from synthetic S/Se­
alkylated Met analogs ( 42 analogs) or commercial sources 55 
(3 analogs). 
Interestingly, in contrast to its low sequence similarity to 
other MATs, sMAT displays the typical three-domain fold 
and partly conserved active site architecture. Unlike other 
known MAT structures, the activity of sMAT cannot be 60
stimulated by ionic potassium [47]. This can be supported 
structurally by the presence of a lysine side chain (K63) in 
sMAT, which likely has a similar function to potassium ion 
in other MATs. Further, the capture of the first atypical 
ligand bound structure of MAT provides insights on the 65 
nature of sMAT broad substrate specificity and a template 
for expanding the substrate scope. The present disclosure 
expose sMAT as an efficient catalyst for SAM analog 
production that is amendable to downstream SAM-utilizing 
processes. 
Overall Structural Organization: 
The crystal structures of sMAT have been determined 
successfully at 2.19 A or 2.39 A resolution for the SAM­
liganded form, 2.49 A for the SAE-liganded form and 2.21 
A for the unliganded form. Similar to E. coli MAT ( eMAT) 
[52], Rat liver MAT (r!MAT) [35], human MATs (hMATlA 
and hMAT2A) [ 49], sMAT packs as a tetramer. All four 
sMAT structures contain two subunits, A and B, in the 
asymmetric unit and the tetramer is formed by a 2-fold 
crystallographic symmetry axis. The buried surface interface 
between the two subunits A and B, and the two dimers AB 
and CD are calculated to be 2570 and 1870 A2 respectively
[41]. In the tetramer, there are four potential ligand-binding 
sites: two sites sandwiched by A and B, and the other two 
sites between C and D. Compared with other known MAT 
structures [43], the sMAT monomer adopts a similar 3-do­
main architecture with secondary structure variants. Inter­
estingly, unlike other MATs, structural variations were 
observed between subunits A and B in sMAT with an 
average root mean square deviation (rmsd) of0.51 A in both 
the liganded and unliganded structures. In addition, the 
maximum rmsd between all the A subunits and the maxi­
mum rmsd between all the B subunits in all sMAT structures 
are calculated as 0.29 A and 0.21 A, respectively. As a result, 
half of the active sites are in a more open conformation. 
Active Site Contents: 
The MAT catalyzed SAM formation occurs via a sequen­
tial two-step mechanism. In the first step, SAM is formed by 
a direct SN2 reaction, in which the sulfur atom of methionine 
attacks the CS' position of ATP and thus cleaves the poly­
phosphate chain from ATP. In the second step, the triphos­
phate is further hydrolysed to diphosphate (PPi) and phos­
phate (Pi)[43]. Komoto et al. identified two critical residues, 
lysine 165 and histidine 14, in eMAT for this proposed SN2 
reaction based on their ligand-bound structures. Interest­
ingly, even with significant sequential variations to eMAT 
and other MATs, several conserved residues were observed 
in sMAT, mainly located around the active site, including the 
two crucial residues, lysine (K201) and histidine (H29) for 
the proposed SN2 reaction. 
The interaction between sMAT and products in the active 
site are multifaceted. The adenine ring of SAM is recognized 
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by a hydrogen bond with the side chain of aspartate 144 and 
a stacking interaction with the aromatic ring of tyrosine 270. 
Several water molecules surrounding by the adenine ring 
also form a hydrogen bond network to the enzyme. The 
2'-0H and 3'-0H of the adenosine ribose interact with the 5 
For the comparison of active site residues, crystal struc­
tures of sMAT, eMAT [ 40] and hMAT2A [ 49] were aligned 
by ligands as described in the methods section. Surprisingly, 
16 of 17 active site residues detected in sMAT have an 
identical or similar residue in eMAT and hMAT2A. The only 
extra residue sMAT has is H315 , which forms hydrogen side chains of aspartate 199, aspartate 282 and serine 277. 
Similar interactions involving aspartic acids have been seen 
in other MAT structures bound with SAM, but not for serine 
[40, 50]. The methionine/ethionine moiety (of SAM and 
SAE, respectively) forms hydrogen bonds with four resi­
dues, in which the amino group interacts with the side chain 
of aspartate 282, and the carboxylate group interacts with the 
side chain of histidine 58, asparagine 60 and asparagine 159. 
The methyl or ethyl group is buried in a slightly hydrophobic 
pocket surrounded by asparagine 159, aspartate 160, isoleu­
cine 349, leucine 145 and the adenine ring. As similar 
observations in eMAT [40], the PPi and Pi formed a 
U-shaped conformation with two magnesium ions closely
stacked on both sides. Further, the two magnesium sites are
formed with the side chains of aspartate 31, glutamate 305
and three water molecules. The phosphate groups are sur­
rounded and stabilized by the side chains of several basic
amino acids: lysine 25, histidine 29, lysine 201, arginine 288
and lysine 310.
As described, the ligands are solvent inaccessible and 
thus, the entrance of the active site requires a dynamic and 
flexible region. A flexible loop region was previously iden­
tified as the gate for the active site in MATs [53]. This gate 
loop feature has been confirmed by crystal structures of 
eMAT, hMAT2A and hMAT2B, in which the loop becomes 
ordered when ligands are bound and it becomes disordered 
when the active site is empty [40, 50]. A similar gating loop 
region was identified in sMAT, which has interactions with 
the adenine ring and the methionine or ethionine moiety. 
bond with 05 in di-phosphate. DALI-based sequence align­
ment was able to identify 11 pairs ofresidues. Eight of them 
are conserved among sMAT and other MATs, including the 
10 crucial residues histidine and lysine for the proposed SN2-
like mechanism [40]. The other three pairs are very similar 
residues at the same spot: for example, in sMAT tyrosine 270 
forms stacking interactions with the adenine ring of SAE/ 
15 SAM, while in eMAT it is phenylalanine 230. Intriguingly, 
there are another 5 pairs of residues that are not detectable 
via DALI search: the side chain of sMAT lysine 25 ( eMAT 
lysine 245) helps stabilize the tri-phosphate group; the side 
chains of sMAT histidine 58 and asparagine 60 (eMAT 
20 glutamine 98 and lysine 269) form hydrogen bonds with the 
carboxyl group of methionine or ethionine; the side chain of 
sMAT glutamate 305 (eMAT aspartate 271) form ionic 
bonds with the magnesium ion; the side chain of sMAT 
lysine 63 occupies the same spot as the eMAT potassium ion 
25 and helps stabilize the di-phosphate ligand. 
Unlike other known MATs, it has been previously 
reported that the activity of sMAT cannot be enhanced by K+ 
[47]. In the present study, all the crystals of sMAT were 
obtained from the crystallization condition containing more 
30 than 150 mM potassium, but electron density suitable for K+ 
was not observed in any datasets. Combined with the active 
sites alignment evidence, it is very likely that the catalytic 
activity of sMAT is not affected by K+, because the lysine in
sMAT serves to present the requisite cation properties. 
Unusual Product Formation During Crystallization: Two 35 
sets of ligand bound crystals were obtained in the presence 
Substrate Specificity of sMAT: 
The substrate specificity for sMAT based upon RP-HPLC 
is illustrated in FIG. 16 wherein observed 5'-methyl-thio 
(seleno )-5'-deoxyadenosine (MTA) production (via 
RP-HPLC) was interpreted as product based upon the well-
of 5 mM ADP, 10 mM ethionine (or methionine), 10 mM 
Mg2+ ion, and 1.4 M NaHPOiK2HP04. Thus based on the
simulated annealing Fo-Fc omit map of the active site, one 
ADP, one P04, two Mg2+ and one ethionine ( or methionine)
molecule were initially built in. However, this model does 
not fit the electron density perfectly, because the Fo-Fc omit 
map does not agree with the placement of the crucial carbon 
atom. Thus, it is very clear that the product has already 
formed and a model including PPi and SAE ( or SAM) is 
more appropriate. The new model has a lower temperature 
factor and a better real-space correlation to electron density 
40 established SAM decay pathways indicating M TA to 
directly derive from SAM (not ATP). [18, 11, 57] Of the 45 
putative substrates tested with sMAT, 11 led to appreciable 
(>50%) SAM analog production, an additional 15 led to 
moderate (25-50%) conversion, while 5 offered detectable 
45 product ( <25%) under the conditions described. In general, 
smaller alkyl substitutions were better tolerated, suggesting 
steric infringement to possibly prohibit larger substitutions. 
Interestingly, in the case where direct comparisons could be 
made, the degree ofunsaturation correlated with a reduction 
in the active site. MAT-catalyzed SAM/SAE formation via 
ADP and Met/Eth has not been previously observed. In 
addition, incubation of sMAT in the presence of ADP and 
methionine at 65 ° C. for 4 hr under standard assay condi­
tions led to no detectable product. Thus, two explanations 
for this unusual product formation have been proposed: (i) 
The sMAT protein is contaminated by ATP during expres­
sion or purification; (ii) The unusual reaction catalyzed by 55 
sMAT can actually occur in vitro, but may take as long as 
one month to finish, which corresponds to the length of 
crystal growth in this experiment. 
50 in turnover ( e.g., propyl>allyl>propargyl). Importantly, 
notable turnover was observed with branched analogs (FIG. 
16) that previously led to only trace product with MATs
studied to date.
Structure Homology: 
A DALI search [38] for structures similar to the sMAT 60 
monomer returned several hits, all of which are previously 
solved MAT structures with Z-scores between 23 and 29. 
Those MAT structures share a very high level of overall 
sequence identity (>50%) and a high level of conservation 
among residues associated with substrates binding. Interest- 65 
ingly, sMAT only has a maximum sequence identity of 19% 
with these known MATs, but shares a similar three-domain. 
A comparison of the kinetic parameters for L-methionine 
and the non-native substrate for which a ligand-bound 
structure is available (L-ethionine) reveals that the profi­
ciency of the sMAT increases for both the substrates with an 
increase in temperature from 37° C. to 65 ° C., and correlates
to both an increase in kcat and a decrease in Km. At either 
temperature, the kcat values for the sMAT reaction with 
L-methionine or L-ethionine are similar and the reduced
proficiency with L-ethionine when compared to the native
substrate L-methionine derive from a combination of higher
Km values for both L-ethionine and ATP. 
Interestingly, eMAT and hMAT2A also have some ability 
to incorporate ethionine. The ethionine turns over with 
sMAT, and hMAT2A is near 100%, whereas eMAT is just 
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10%. A ligand-based alignment shows that sMAT has a 
larger cavity around the ethyl/methyl group than either 
hMAT2A or eMAT. 
48 
0.15-0.2 mM sMAT and 25 mM Tris pH 8.0. For sMAT: 
(SAM) condition, the protein solution contains 0.15-0.2 mM 
sMAT, 1 mM SAM and 25 mM Tris pH 8.0. For sMAT: 
(ADP+Met/Eth), the protein solution contained 0.2-0.3 mM 
sMAT, 5 mM ADP, 10 mM Met (or Eth), 10 mM MgCl2, 
12.5 mM KC!, 7.5 mM DTT  and 25 mM Tris pH 8. All 
crystals were cryoprotected by 25% DMSO or 25% ethylene 
glycol and flash frozen in liquid nitrogen. 
Also, branched analogs highlighted in FIG. 16 turnover 
significantly better with sMAT, comparing with eMAT, 5 
hMAT2A and mMAT (MAT from Methanocaldococcus jan­
naschii). Interestingly, mMAT is a thermophilic archaea 
MAT that has all active site residues conserved with sMAT. 
However, further comparison between their active site cavi­
ties cannot be conducted, because mMAT structure remains 
unknown. The current structural information suggests the 
better turnover rate of branched SAM analogs with sMAT is 
possibly mediated by some general orientation/dynamics of 
the gating loop and/or secondary shell variations. 
X-ray diffraction data were collected at the Life Science
1° Collaborative Access Team (LS-CAT) with an X-ray wave­
length of 0.98 A for all sMAT crystals at the Advanced 
Photon Source at Argonne National Laboratory. Datasets 
were indexed and scaled by HKL2000 or XDS [39, 46]. For 
15 structure solution of apo sMAT, phenix.HySS was used for 
determination of selenium atom sub-structure, AutoSol for 
phasing and phenix.autobuild for model building (Adams et 
al., 2010). For the other structures of sMAT with ligands, 
molecular replacement was utilized using the apo sMAT 
Conclusions: sMAT has the characteristic fold and the 
typical tetramer assembly of known MATs. In addition, the 
slightly expanded substrate scope of sMAT over other MATs 
studied to date highlight sMAT as a useful tool for the 
production of SAM analogs. In conjunction with the dem­
onstration of coupled MAT-methyltransferase systems for 
differential alkylation, this chemoenzymatic strategy cir­
cumvents a major liability in the use of synthetic SAM 
analogs-namely, the dramatic instability of the SAM ana­
logs. 
Further, the elucidation of the active site architecture with 
the atypical product bound, the characterization of the gating 
loop region, as well as the sMAT turnover reactions with 
different SAM analogs provide a blueprint for future SAM 
analog production. 
Materials and Methods 
Expression and Purification of sMAT: 
The methionine adenosyltransferase (MAT) gene (Uni­
Prot accession: Q980S9) was cloned into NdeI/EcoRI-di­
gested pET28a to enable production of recombinant N-Hisc 
sMAT). For protein production, the corresponding pET28a­
sMAT construct was transformed into the E. coli methionine 
auxotroph strain 8834 (DE3) and auto-induction media 
(Sreenath et al., 2005) was used for expression at 37° C. The 
cells were harvested by centrifugation at 5000 rpm for 30 
min and resuspended in buffer 20 mM NaH2P04, 300 mM 
NaCl, 10 mM imidazole pH 7.8. The cells were lysed via 
lysozyme incubation followed by sonication on ice. Subse­
quently, N-His6-sMAT was purified via Ni-NTA chelating 
colunm (GE Healthcare) following a protocol with a linear 
imidazole (10-500 mM) elution gradient (50 mM NaH2P04, 
300 mM NaCl, pH 8.0) The Hisctag was removed by 
thrombin (Novagen) cleavage and the affinity tag was 
removed via a second round of Ni-NTA affinity chromatog­
raphy. After the buffer exchange using PD-10 colunm (25 
mM Tris-HCI, pH 8), the desired truncated Se-sMAT was 
concentrated to 27 mg/mL, flash frozen in liquid nitrogen 
and stored at -80° C. Protein concentrations were deter­
mined by Bradford assay (Bio-Rad, Hercules, Calif., USA) 
using BSA as a standard. Unless otherwise indicated, the 
term sMAT herein refers to SeMet-labeled sMAT after 
thrombin cleavage. 
Crystallization, Diffraction, and Structure Determination: 
General screens were performed with PEGRx HT, Crystal 
Screen HT, Index HT, and SaltRx HT (Hampton Research) 
utilizing a Mosquito® dispenser ( TTP labTech) by the 
sitting drop method. Crystal growth was monitored by 
Bruker Nonius Crystal Farms at 20° C. All sMAT crystals 
with or without substrates were obtained by mixing 2 µL of 
protein solution and 2 µL of reservoir solution, 1.40 M 
sodium phosphate mono basic monohydrate/potassium phos­
phate dibasic pH 5.6, using the sitting drop method. For 
unbound sMAT crystals, the protein solution contained 
20 structure as a starting model. The structures including sev­
eral double conformations were manually rebuilt in several 
rounds by Coot [33] and further refined by phenix.refine 
[31]. Mo!Probity was used to validate the quality of the 
coordinates [32]. All structural figures in this paper were 
25 generated using PyMOL [48]. 
Ligand-based Structural alignment of MAT homologs: In 
order to best compare the active site contents between 
structures with low sequence identity, four structures were 
30 aligned based on ligand positions by PyMOL. They are 
eMAT with SAM and PPNP (PDB code 1RG9) [ 40], 
hMAT2A with SAM (PDB code 2P02) [49], sMAT with 
SAM, PPi and P04 (PDB code 4KOB) and sMAT with SAE, 
35 PPi and P04 (4L2Z). 1RG9, 2P02 and 4KOB were first 
aligned by SAM molecule, and thus 4L2Z was aligned to 
4KOB via several active site residues. Atom clashes were 
calculated in presence of hydrogen atoms using Py MOL and 
40 
displayed as bumps. 
In-vitro sMAT assay: In vitro sMAT reactions were con­
ducted in a volume of 50 µI with 2 mM S/Se-alkylated 
analog, 1 mM ATP and 5 µM purified sMAT in 25 mM Tris 
buffer pH 8.0, 5 mM MgCl2, 50 mM KC! for 4 h at 65
° C. 
45 Reactions were quenched by adding an equal volume of 
methanol followed by centrifugation (10,000xg for 15 min) 
to remove the precipitated protein and product formation for 
each reaction was subsequently analyzed by reverse phase 
50 HPLC (RP-HPLC) using method described below. For each 
reaction, percent yield was based upon the integration of 
species at 254 nm and calculated by dividing the integrated 
area of product and/or decomposed product by the sum of 
55 integrated area of product and/or decomposed product and 
the remaining substrate. The assays were repeated twice 
under identical conditions, and Table 4 (and FIG. 17) 
represents an average value of two assays. The inclusion of 
60 adenine and 5'-R-thio-5'-adenosine in these calculations is 
based upon the established SAM and ATP chemical decom­
position pathways which indicate adenine and 5'-R-thio-5'­
adenosine to only derive from SAM (not ATP). All putative 
65 
products were subsequently confirmed by high resolution 
electro spray ionization (ESI) mass spectra with positive ( +) 
and/or negative ( -) mode. 
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TABLE 4 
of sMAT reactions 
Percentage Turn-Over Theoretical mass Observed mass 
100 399.1445, 297.0896[a] 399.1444, 298.0965[b] 
100 447.0890, 345_034o[a] 447.0895, 346.0416[b] 
84 413.1602, 311.1052[a] 413.1599, 312.1121[b] 
76 461.1046, 359.0497[a] 416.1040, 360.0565[b] 
36 321.0896[a] 322.1051 [b] 
28 369.0340[a] 370.0411 [b] 
ND NA NA 
68 322.0848[a] 323.0919[b] 
12 370.0293[a] 371.0371 [b] 
27 425.1602, 323.1052[a] 425.1609, 324.1129[b] 
30 371.0497[a] 372.0568[b] 
44 427.1758, 325.1209[a] 427.1759, 326.1281[b] 
66 475.1203, 373.0653[a] 475.1200, 374.0720[b] 
53 427.1758, 325.1209[a] 427.1762, 326.1282[b] 
40 373.0653[a] 374_0743[b] 
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TABLE 4-continued 
Surnrn of sMAT reactions 
eoretlcal mass Percentage Turn-Over Th Observed mass 
30 
10 
27 
15 
46 
27 
70 
57 
ND 
ND 
14 
50 
36 
12 
437.1602, 335.1052[a] 437.1599, 336.1124[b] 
383.0497[a] 384.0566[b] 
439.1758, 337.1209[a] 439 1754 · , 338.1275[b] 
439.1758, 337.1209[a] 439 1754 · , 338.1282[b] 
385.0653[a] 386.0730[b] 
441.1915, 339.1365[a] 441 1966 · , 340.1477[b] 
489.1359, 387.0810[aJ 489 1358 · , 388.0882[b] 
441.1915, 339.1365[a] 441 1918 3 · , 40.1439[b] 
NA NA 
NA NA 
451.1758 451.1756 
454.1616, 352.1066[a] 454.1615, 353.1140[b] 
455.2071, 353.1522[a] 455 2123 35 · , 4.1634[b] 
453.1915 453.2044 
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TABLE 4-continued Surnrn of sMAT reactions 
Analog Percentage Turn-Over Theoretical mass Observed mass /Se� 44 399.0810[aJ 400.0878[b] 
/SD 
ND NA NA 
/s.D ND NA NA /S� N3 60 468.1772, 366.1223[a] 468.1772, 367.1296[b] 
lsv 
ND NA NA 
/s,v 
ND NA NA 
ls� N3 28 480.1772, 378.1223[a] 480.1768, 379.1292[b] 
24 426.0667[a] 427.0687[b] 1� N3 Se 
38 400.0762[a] 401.0830[b] 1� NH2 Se 
/s
� 
ND NA NA 
/s� 
ND NA NA 
/s�
No, 
ND NA NA 
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TABLE 4-continued 
Summ of sMAT reactions 
56 
Analog Percentage Turn-Over Theoretical mass Observed mass 
;
(�NO, 
;
(� s '/',(OOH 
NH2 
NH2 
/S�S�COOH 
ND NA NA 
ND NA NA 
ND NA NA 
ND NA NA 
[a]theoretical mass of degraded 5'-alkyl-thio(seleno)-5'-deoxyadenosine (MTA); observed mass of degraded 5'-alkyl thio(seleno)-5'-deoxyadenosine (MTA): 
[bl[M+H]; 
NDnot detected; 
NAnot applicable. 
RP-HPLC method: Reactions were quenched by the addi­
tion of equal volume of methanol followed by centrifugation 
at 10,000 g for 15 min to remove precipitated protein before 
applying on an analytical Varian ProStar HPLC [Luna C18 35 
column, 5 µm, 4.6 mmx250 mm; Phenomenex, Torrance, 
Calif., USA; gradient of 10% B to 40% B over 15 min, 40% 
B to 75% B over 5 min (A=lO mM NaH2P04, 5 mM octane 
sulfonic acid, pH was adjusted to 3.5 using phosphoric acid; 
B=acetonitrile) flow rate= 1 mL min-1; A254]. Reaction prod- 40 
ucts were confirmed by HRMS. 
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Kinetic Measurements of sMAT Reactions: Pseudo first­
order kinetics was assessed in triplicate under saturating 
ATP (2.5 mM) and variable L-methionine/L-ethionine 
(0.007, 0.013, 0.033, 0.066, 0.133, 0.333, 0.66, 1.33 mM) 
and saturating L-methionine/L-ethionine (2.5 mM) and vari­
able ATP (0.013, 0.033, 0.066, 0.133, 0.333, 0.66, 1.33 mM) 
concentrations. Reactions were performed in buffer contain­
ing 25 mM Tris pH 8.0, 40 mM KC! and 5 mM MgCl2, and 
0.5 µg purified sMAT was added and incubated at 37° C. or 50 
65° C. in a final volume of 20 µL. Reaction products were 
analyzed using RP-HPLC method above and product quan­
tification was carried out using standard curve generated by 
commercial SAM. The kinetic curves were fit to the Michae-
!is-Menton equation using Prism software. 55 
Example III 
FIG. 19 illustrates a reaction catalyzed by MAT. Relat­
edly, FIG. 20 presents the synthesis of methionine-tetrazole 60 
(Met-T or T-Met), where: (a) is (Boc)20, pyridine, 
NH4HC03, rt, 5 h, 70-8-%; (b) is ( TFA)20: pyridine (1:1), 
THF, 0° C., 3 h, 85-95%; (c) is NaN3, ZnBr2, H20/2-
propanol (2: 1 ), 80° C., 16 h, 80-90%; and ( d) is Et2NH, 
CH2Cl2, 0.5 h, 80-94%. And FIG. 21 provides data illus- 65 
trating the increased stability of SAM- T relative to native 
SAM. 
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SEQ ID NO: 1 is the DNA sequence of synthetic Metha­
nocaldococcus jannaschii MAT (mMAT) gene where the 
bold letters indicate engineered restriction sites for subclon­
ing (5'-NdeI and 3'-EcoRI). 
5'-CATATGCGTAATATCATTGTGAAAAAACTGGATGTGGAACCGATTGA 
AGAACGCCCGACGGAAATTGTTGAACGTAAAGGTCTGGGTCATCCGGATT 
6° CAATTTGCGACGGTATCGCCGAAAGCGTGTCTCGCGCACTGTGTAAAATG 
TACATGGAAAAGTTTGGCACGATTCTGCATCACAATACCGATCAGGTCGA 
ACTGGTGGGCGGTCATGCTTATCCGAAGTTTGGCGGTGGCGTCATGGTGT 
65 CACCGATTTACATCCTGCTGTCGGGTCGTGCAACCATGGAAATCCTGGAT 
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-continued
AAGGAAAAGAATGAAGTCATCAAGCTGCCGGTGGGTACCACGGCAGTTAA 
62 
-continued
GGTTAATCACGTCGGCAAGATTTATAACATCCTGGCGAATCTGATTGCCA 
AGCAGCCAAGGAATATCTGAAAAAGGTCCTGCGTAACGTTGATGTCGACA 
ACGATATCGCAAAACTGGAAGGTGTCAAGGAATGTTACGTGCGTATTCTG 
AAGATGTTATTATCGATTGCCGCATTGGTCAGGGCAGCATGGACCTGGTG 
TCACAAATCGGCAAACCGATTAATGAACCGAAGGCCCTGGATATCGAAAT 
GATGTTTTTGAACGCCAGAAAAACGAAGTGCCGCTGGCTAACGACACGAG 
TATCACCGAAGACTCGTACGATATTAAAGACATCGAACCGAAAGCTAAGG 
TTTCGGTGTTGGCTACGCGCCGCTGTCCACCACGGAACGTCTGGTGCTGG 
AAATTGCGAACAAATGGCTGGACAACATTATGGAAGTTCAGAAGATGATC 
AAACCGAACGTTTTCTGAACAGCGATGAACTGAAAAACGAAATCCCGGCG 10 
GTCGAAGGCAAGGTCACCACGTTTTGAGAATTC-3' 
GTTGGTGAAGACATTAAAGTCATGGGTCTGCGTGAAGGCAAAAAGATTAC 
SEQ ID NO: 2 is 
CCTGACGATCGCGATGGCCGTGGTTGATCGCTATGTGAAGAACATCGAAG 
AATACAAAGAAGTGATCGAAAAGGTTCGTAAAAAGGTCGAAGATCTGGCA 15 5'-ATACTGCATATGGCAAAACACCTTTTTACG 
AAAAAGATCGCTGACGGCTATGAAGTTGAAATCCACATTAACACGGCCGA (forward, Ndel). 
TGACTATGAACGCGAATCCGTGTACCTGACCGTTACGGGTACCAGCGCAG SEQ ID NO: 2 is 
AAATGGGTGATGACGGCTCTGTGGGTCGTGGCAACCGCGTTAATGGCCTG 
20 
5'-CAGTATGGATCCTTACTTCAGACCGGCAGC 
ATTACCCCGTTCCGTCCGATGAGTATGGAAGCAGCTTCCGGTAAAAACCC 
(reverse, BamHI). 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 5 
<210> SEQ ID NO 1 
<211> LENGTH, 1230 
<212> TYPE, DNA 
<213> ORGANISM, Methanocaldococcus jannaschii 
<400> SEQUENCE, 1 
catatgcgta atatcattgt gaaaaaactg gatgtggaac cgattgaaga acgcccgacg 60 
gaaattgttg aacgtaaagg tctgggtcat ccggattcaa tttgcgacgg tatcgccgaa 120 
agcgtgtctc gcgcactgtg taaaatgtac atggaaaagt ttggcacgat tctgcatcac 180 
aataccgatc aggtcgaact ggtgggcggt catgcttatc cgaagtttgg cggtggcgtc 240 
atggtgtcac cgatttacat cctgctgtcg ggtcgtgcaa ccatggaaat cctggataag 300 
gaaaagaatg aagtcatcaa gctgccggtg ggtaccacgg cagttaaagc agccaaggaa 360 
tatctgaaaa aggtcctgcg taacgttgat gtcgacaaag atgttattat cgattgccgc 420 
attggtcagg gcagcatgga cctggtggat gtttttgaac gccagaaaaa cgaagtgccg 480 
ctggctaacg acacgagttt cggtgttggc tacgcgccgc tgtccaccac ggaacgtctg 540 
gtgctggaaa ccgaacgttt tctgaacagc gatgaactga aaaacgaaat cccggcggtt 600 
ggtgaagaca ttaaagtcat gggtctgcgt gaaggcaaaa agattaccct gacgatcgcg 660 
atggccgtgg ttgatcgcta tgtgaagaac atcgaagaat acaaagaagt gatcgaaaag 720 
gttcgtaaaa aggtcgaaga tctggcaaaa aagatcgctg acggctatga agttgaaatc 780 
cacattaaca cggccgatga ctatgaacgc gaatccgtgt acctgaccgt tacgggtacc 840 
agcgcagaaa tgggtgatga cggctctgtg ggtcgtggca accgcgttaa tggcctgatt 900 
accccgttcc gtccgatgag tatggaagca gcttccggta aaaacccggt taatcacgtc 960 
ggcaagattt ataacatcct ggcgaatctg attgccaacg atatcgcaaa actggaaggt 1020 
gtcaaggaat gttacgtgcg tattctgtca caaatcggca aaccgattaa tgaaccgaag 1080 
gccctggata tcgaaattat caccgaagac tcgtacgata ttaaagacat cgaaccgaaa 1140 
gctaaggaaa ttgcgaacaa atggctggac aacattatgg aagttcagaa gatgatcgtc 1200 
US 9,879,043 Bl 
63 64 
-continued
gaaggcaagg tcaccacgtt ttgagaattc 
<210> SEQ ID NO 2 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM: Neisseria denitrificans 
<400> SEQUENCE, 2 
atactgcata tggcaaaaca cctttttacg 
<210> SEQ ID NO 3 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Bacillus amyloliquefaciens 
<400> SEQUENCE, 3 
cagtatggat ccttacttca gaccggcagc 
<210> SEQ ID NO 4 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM: Neisseria denitrificans 
<400> SEQUENCE, 4 
agccatatga aaatcggcat cattggtg 
<210> SEQ ID NO 5 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Excherichia coli 
<400> SEQUENCE, 5 
atagaattct tagccatgtg caagtttctg 
What is claimed is: 
1. An S-adenosyl-L-methionine (SAM) or Se-adenosyl-
40 
L-methionine (SeAM) analog of the Formula III:
(III) 
wherein X is selected from the group consisting of S and 
Se; 
45 
50 
wherein, when X is S, R1 is selected from the group 
55 
consisting of: 
\'c�,�N,�, 
\lYy·�· 
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wherein, when X 1s Se, R1 1s selected from the group 
consisting of: 
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2. A compound of the Formula II:
wherein R1 is selected from the group consisting of 
/x� S �COOH 
NH2 
NH2 
/
X�S�COOH, and 
/X� S �COOH 
NH2 
and Xis S. 
(II) 
3. An S-adenosyl-L-methionine analog of the Formula III:
(III) 
wherein X is S and R1 is selected from the group con­
sisting of: 
10 
15 
20 
25 
66 
�
S
�
COOH, 
NH2 
�H2 
�S�COOH, and 
4. An S-adenosyl-L-methionine (SAM) analog of the
formula: 
5. A method of producing an S-adenosyl-L-methionine
analog according to claim 4, comprising the step of reacting 
a first substrate comprising methionine-tetrazole with a 
second substrate comprising adenosine triphosphate (ATP) 
30 in the presence of a methionine adenosyltransferase (MAT). 
6. The method of claim 5, wherein the MAT comprises at
least one of human MAT II catalytic alpha and regulatory 
beta subunit (hMAT2), human MAT II catalytic alpha sub­
unit alone (hMAT2A), human MAT I catalytic subunit alpha 
35 (hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol­
fataricus MAT (sMAT), and Methanocaldococcus janna­
schii MAT (mMAT). 
7. A method of producing the S-adenosyl-L-methionine
analog of claim 1, comprising the step of reacting a first 
substrate comprising a methionine analog with a second 
40 substrate comprising adenosine triphosphate (ATP) in the
presence of a methionine adenosyltransferase (MAT). 
8. The method of claim 7, wherein the MAT comprises at
least one of human MAT II catalytic alpha and regulatory 
beta subunit (hMAT2), human MAT II catalytic alpha sub-
45 unit alone (hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol­
fataricus MAT (sMAT), and Methanocaldococcus janna­
schii MAT (mMAT). 
9. The method of claim 7, wherein the first substrate is of
50 the Formula II: 
(II) 
55 
wherein R1 is selected from the group consisting of 
65 
US 9,879,043 Bl 
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(II) Ix� !x�!x�
N, , , 5 
!x�,!x�,!s�. ! x�.
Ix�, !x�NH2, 
ls1!s� 
!s�N,!s� 
!x�!xD
!S�N; !Xv 
Is� 
Is��·· 
! xuN�;=•
wherein X is S. 
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wherein R1 is selected from the group consisting of 
Ix�. !x�N 
!x�!x�
!x�,!x�,!x�·!x�
!x�NH,!x�
!xD ! xv
!x�N3,
wherein X is Se. 
12. A method of producing an indolocarbazole analog,
comprising the step of reacting a first substrate comprising 
55 a methionine analog with a second substrate in the presence 
of a methionine adenosyltransferase (MAT), wherein the 
methionine analog is of the Formula II: 
10. A method of producing the Se-adenosy 1-L-methionine
60 
analog of claim 1, comprising the step of reacting a first (II) 
substrate comprising a methionine analog with a second 
substrate comprising adenosine triphosphate (ATP) in the 
presence of a methionine adenosyltransferase (MAT). 
11. The method of claim 10, wherein the first substrate is
of the Formula II: 
65 
US 9,879,043 Bl 
69 
wherein R1 is selected from the group consisting of 
Ix� Ix�. ls -.c,.Ix� lx�lx� 
N, , lx�,lx�, ls�.IX'i(·
Ix�, lx�NH2, ls1ls�
ls�N,ls�
lx�lxD 
IS�N; l xv
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-continuedlx�N3,lse�NH2, and Is�
Is�-, 
lxu N02; 
wherein X is selected from the group consisting of S and 
Se; and 
wherein the second substrate comprises at least one 
indolocarbazole group. 
13. The method of claim 12, wherein the MAT comprises
at least one of human MAT II catalytic alpha and regulatory 
beta subunit (hMAT2), human MAT II catalytic alpha sub­
unit alone (hMAT2A), human MAT I catalytic subunit alpha 
35 (hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol­
fataricus MAT (sMAT), and Methanocaldococcus janna­
schii MAT (mMAT). 
* * * * *
